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ABSTRACT
Ectodermal dysplasias (ED) are a group of developmental disorders in which
ectodermally derived structures are abnormally formed or absent entirely. The molecular
signaling pathway controlling the differentiation of ectodermal appendages has been well
documented in recent years. However, questions remain concerning the key signaling
molecule of this pathway, ectodysplasin-1 (EDA), the identity of the EDA signaling
pathway’s target genes, and the presence of additional phenotypes observed in some
patients.
Despite the intensive study of EDA in recent years, the functional significance of the
N-terminal intracellular domain of ectodysplasin-1 (N-EDA) has remained elusive. The
yeast two-hybrid system was employed to further the understanding of this domain in the
EDA protein. RBM39 has been identified as a potential interacting protein with N-EDA.
Fluorescence microscopy has also demonstrated that these proteins co-localize to the
nucleus, a novel finding for N-EDA.
In an attempt to identify additional genes involved in the EDA pathway that may be
responsible for ED phenotypes, the translocation breakpoint regions of a patient with a
chromosomal translocation t(1;6) and clinical features of ED with mild mental retardation
(MR) have been partially mapped. Candidate genes have been identified near both
translocation breakpoint regions.
Finally, an additional clinical feature found in some ED patients is MR of varying
severity. To help understand the etiology of MR in one ED patient with a 9p subtelomeric
aberration, positional cloning was used to identify DOCK8 as the potential causative gene for
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the MR phenotype. These results were supported by the identification of a second patient
with MR in which a 9p subtelomeric deletion also disrupts DOCK8. The findings of this
study indicate that haploinsufficiency of DOCK8 is likely responsible for the MR in these
two patients and suggest a putative role for DOCK8 in brain development and function.
The differentiation of ectodermal appendages is a complex process in which
mutations in genes at any step of EDA signaling can result in ED phenotypes. These studies
contribute to the understanding of how ectodermally derived structures form, both through
the discovery of novel functions for N-EDA and the identification of a new candidate target
gene involved in the EDA signaling pathway. Finally, these results also provide possible
causative genes for MR observed in one patient with ED.
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PREFACE
Ectodermal dysplasias (ED) are a group of genetically diverse developmental
abnormalities which involve structures that originally derive from the ectodermal germ layer.
There are over 150 clinically distinct ectodermal dysplasias variably affecting teeth, hair,
fingernails, sweat gland, and the sebaceous gland (Pinheiro and Freire-Maia, 1994; Mikkola
and Thesleff, 2003).
Hypohidrotic ectodermal dysplasia (HED) is one of the most common forms of this
disorder. HED is characterized by the absence or deficient function of at least two
derivatives of the ectoderm: hair, teeth, sweat glands, or nails. The varied phenotype
includes sparse scalp and body hair, anodontia or oligodontia with conical shaped teeth, and
a lack of eccrine sweat glands. Additionally, there can be a distinctive facies with prominent
forehead and lips, depressed nasal bridge, and darker pigmentation around the eyes (Clarke,
1987). HED potentially can be life threatening because of the lack or reduced number of
functional eccrine sweat glands. This abnormality leads to difficulty in maintaining body
temperature and places the patient at risk for hyperthermia. A mortality rate quoted at up to
30% is reported if affected individuals are not diagnosed in the first two years of life
(Mikkola and Thesleff, 2003).
Historically, HEDs have been described in the scientific literature for over 150 years.
In 1848, Thurman described two cases where the skin, hair and teeth were not properly
developed (Clarke, 1987). Charles Darwin described HED with the toothless men of Sind in
1875 in his book, “The Variations of Animals and Plants Under Domestication” and
documented precisely the ED phenotypes and male specific inheritance pattern (Kere et al.,
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1996). The 1938 Works Progress Administration guide on Mississippi described a large
family of former slaves with HED (Srivastava et al., 2001). Although HED has been
described in the literature for some time, the molecular basis for the disorder has only
recently been thoroughly understood.
For some time, there were several hypotheses as to the mode of inheritance of HED.
Historically, most of the families displayed an X-linked inheritance pattern and, ultimately,
the disease locus was linked to the long arm of the X chromosome at q12-13 (Kolvraa et al.,
1986). The first evidence supporting autosomal recessive inheritance was demonstrated with
a report of five families who presented with severely affected female members and negative
gene testing of the X chromosome locus (Munoz et al., 1997). Subsequently, autosomal
recessive and autosomal dominant inheritance patterns were linked to chromosome 2q11q13 (Ho et al., 1998; Baala et al., 1999). Additional autosomal loci have been identified
including sites at 1q and 11p. We now know that approximately 90% of HEDs are
diagnosed as X-linked (Cui and Schlessinger, 2006).
Kere, Srivastava, and co-workers first identified the gene responsible for X-linked
HED in 1996. The authors used positional cloning to identify a predicted 135 residue
transmembrane protein, coded for by the gene ectodysplasin-A (EDA). The gene was
physically disrupted in two patients with X; autosome translocations and four patients with
submicroscopic deletions (Kere et al., 1996). Additionally, point mutations within EDA
were identified in nine other HED patients. Fluorescence microscopy and biochemical
fractionation demonstrated that EDA localizes to the cell membrane (Ezer et al., 1997; Ezer
et al., 1999; Mikkola et al., 1999). COS-7 and MCF-7 cell lines show a tendency to round up
and detach when transfected with EDA, suggesting the EDA protein may have a functional
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role in cell dynamics (Ezer et al., 1997). Interestingly, this protein is involved in epidermal
differentiation and was found to share a high degree of similarity with the tumor necrosis
family (TNF) of soluble ligands (Ezer et al., 1999).
The results of Ezer and co-workers are supported by work in BHK cells, which
shows that antibodies raised against the N-terminal fragment of EDA only stain
permeabilized cells where the protein is visualized around the nucleus and throughout the
endoplasmic reticulum (ER) and Golgi body. Antibodies raised against the C-terminus stain
heavily around the membrane in either permeabilized or non-permeabilized cells (Mikkola et
al., 1999). These results confirm the predicted data that EDA is a type II membrane protein
meaning that the amino terminus is intracellular and the carboxy terminus is extracellular.
The mutant mouse tabby (Ta) has an X-linked phenotype similar to HED in
humans, with involvement of the hair, teeth, and sweat glands. The causative gene for the
tabby phenotype, named tabby (ta) for the mouse model, was identified in 1997 and found to
be the homologue of EDA (Srivastava et al., 1997). Ta shares a high degree of structural
similarity to EDA, as well as common temporal and spatial expression patterns (Ferguson et
al., 1997; Srivastava et al., 1997). Ta and EDA share a 94.6% sequence identity at the cDNA
level (Bayes et al., 1998).
Like the tabby mouse, the downless (dl) and crinkled (cr) mouse mutants also have a
phenotype similar to HED, with involvement of hair, teeth, and sweat glands. The gene
affected in the dl mouse was found to be a TNF-like receptor whose human homologue,
EDAR, was mutated in some families with autosomal dominant HED (Headon and
Overbeek, 1999; Monreal et al., 1999). The cr gene, an adapter signaling molecule for
dl/EDAR, was identified as being responsible for the cr mouse mutant (Headon et al., 2001;
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Yan et al., 2002). The human homologue of cr is the EDAR Associated Death Domain
(EDARADD) and is mutated in some families with autosomal recessive ED (Headon et al.,
2001).
Evidence of a role for EDA in epidermal appendage formation has been found in
many species other than human and mouse. A large genomic deletion including exon 3 of
the EDA homologue in cattle was found in a German Holstein family with three maternal
half-siblings affected with HED (Drogemuller et al., 2001). A point mutation affecting the
splicing of exon 9 in the canine homologue of EDA has been reported in a breeding line of
dogs with HED (Casal et al., 2005). The EDA signaling pathway has also been linked to the
development of feather tracts in birds (Houghton et al., 2005). In fish, alternate alleles of
EDA have been identified as the cause of natural variants in the armor plating in
sticklebacks from different environments (Colosimo et al., 2005).
EDA has several splice variants, as shown in Figure P.1. The two longest isoforms,
EDA-A1 and EDA-A2, differ by only 2 amino acids (Bayes et al., 1998). These isoforms
consist of a short intracellular domain, a transmembrane domain, a furin cleavage site, a
collagenous binding domain, and a TNF homology domain (Fig. P.1). The various shorter
isoforms lack many of the domains found near the carboxy terminal portion of the protein.
However, all of the EDA splice variants maintain the intracellular domain and the
transmembrane domain. All of the isoforms, with the exception of EDA-C, localize to the
cell membrane (Ezer et al., 1997; Bayes et al., 1998; Mikkola et al., 1999). Fluorescence
microscopy has shown that EDA-C appears to accumulate around the nucleus, most likely in
the endoplasmic reticulum. It is thought that this isoform is an unstable variant (Ezer et al.,
1999).
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EDA-A1
EDA-A2
EDA-B
EDA-C
EDA-D
EDA-E
EDA-F
EDA-O

391 a.a.
389 a.a.
178 a.a.
147 a.a.
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6 7 8

Collagen Binding
Domain (180-235)

Intracellular Domain (1-40)
NH2

COOH
Transmembrane
Domain (41-63)

TNF Homology Domain
(250-391)

Furin site
(150-159)

Figure P.1 Exon and Protein Structure of Ectodysplasin-A. (a) Exon composition of
each EDA isoform is indicated, as well as EDA genomic localization. (b) Diagram
indicating major functional domains of EDA. The exon responsible for coding for each
domain is indicated by brackets above the diagram. Grey bar beneath schematic
indicates portion of protein common to all isoforms.

EDA isoforms are expressed in different tissue specific patterns (Table P.1) (Kere et
al., 1996; Bayes et al., 1998). Northern analysis of adult and fetal tissues shows a 6 kb band
that corresponds to the full length EDA-A isoforms in all tissues tested, suggesting EDA-A
may be involved in maintenance, as well as differentiation of, ectodermal appendages (Kere
et al., 1996; Bayes et al., 1998). EDA-A and EDA-C are expressed widely and have been
identified in brain, heart, kidney, lung, liver, pancreas, placenta, and skeletal muscle. EDA-B
was reported to be absent in skeletal muscle and EDA-O was not detected in the brain
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(Bayes et al., 1998). No expression of EDA-D was noted in brain, kidney, lung and
pancreas. EDA-E was expressed only in lung, liver, and pancreas (Bayes et al., 1998).

Table P.1 Tissue specific expression of EDA isoforms

Brain
Heart
Kidney
Lung
Liver
Pancreas
Placenta
Sk Muscle
Skin

EDA-A1

EDA-B

EDA-C

EDA-D

EDA-E

EDA-F

EDA-O

+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
*

+
+
+
+
+
+
+
+
*

+
+
+
+
*

+
+
+
*

*

+
+
+
+
+
+
+
*

Adapted from: Human Molecular Genetics 7 (1998) 1661-1669
* Not Determined

Experimental evidence suggests that EDA-A1 is the primary isoform responsible for
triggering secondary differentiation of ectodermally derived structures (Yan et al., 2000;
Schneider et al., 2001; Srivastava et al., 2001). EDA-A2 is thought to function in epidermal
organogenesis and may have a secondary or supporting role to that of EDA-A1 (Yan et al.,
2000; Srivastava et al., 2001). In addition, EDA-A2 has also been implicated in skeletal
muscle homeostasis (Newton et al., 2004).
The final processing of EDA-A1 into a soluble ligand and its subsequent signaling
through downstream targets has been previously reviewed and is summarized in Figure P.2
(Srivastava et al., 2001; Wisniewski et al., 2002; Mikkola and Thesleff, 2003; Botchkarev and
Fessing, 2005; Cui and Schlessinger, 2006). Briefly, EDA-A1 is synthesized in the ER and is
moved to the Golgi body, where it is translocated to the cell membrane. Once on the cell
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membrane, some currently unidentified signal triggers trimer formation. Once the trimer
has formed, EDA-A1 can then be cleaved at the furin-like serine protease site, releasing the
soluble ligand portion of the protein containing the TNF homology domain into the
extracellular matrix. The trimeric molecule then binds to a receptor, EDAR. Binding to the
receptor triggers an intracellular signaling cascade which ultimately activates NF-kB. The

LEF1

EDA
(ta)

EDAR
(dl)

EDA

TAK1

EDARADD TAB2
(cr) TRAF6

active NF-kB, in turn, triggers expression of target genes.

IKK1
NEMO
IKK2

IkB /
NF-kBs
RelA/p50

Wnt
Dkk4/
Dkk1
Shh/Ptc/Gli, BMP/Sostdc1,
LT , Madcam1, etc.

Figure P.2 EDA signaling pathway. EDA-A1 expression is regulated by Wnt. Once
translated, EDA-A1 localizes to the cell membrane where it forms a self trimer, is
cleaved by a furin protease, binds EDAR, and triggers a signalling cascade through
EDARADD, TAB2, TRAF6, and TAK1 to activate NF-kB. Once activated, NF-kB
proceeds to the nucleus where it regulates transcription of EDA-A1’s target genes.
Adapted from: Cell Cycle 5: 2477-83 (2006).
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The process resulting in trimerization of EDA-A1 has not been fully elucidated. The
collagenous domain, which consists of a Gly – X – Y repeat, is known to be required for
trimerization (Ezer et al., 1999; Schneider et al., 2001). In addition, a conserved sequence
between amino acids 61-76 is also likely to have a role in trimer formation (Snellman et al.,
2000). This region (a.a. 61-76) extends from the last two amino acids of the transmembrane
domain into the extracellular domain. Missense mutations within this conserved domain
have been identified in four HED patients (Schneider et al., 2001; Tao et al., 2006).
Missense mutations reported within the collagenous domain, can disrupt trimer formation
while in-frame deletions within the collagenous domain appear to have no effect in trimer
formation (Schneider et al., 2001).
Mutations have been reported in other functional domains of EDA as well. Six
missense mutations have been reported in the furin cleavage domain. When tested
experimentally, a reduction or loss of EDA-A1 proteolytic cleavage was found to result from
these missense mutations, which account for approximately 23% of HED (Schneider et al.,
2001).
All of the missense alterations reported within the TNF homology domain appear to
impede binding with EDAR (Schneider et al., 2001). EDAR, a TNF receptor, is a 448
amino acid type-1 transmembrane protein (Monreal et al., 1999; Koppinen et al., 2001). Like
EDA, EDAR has been found to be conserved through mammals, birds, and fish (Monreal et
al., 1999; Kondo et al., 2001; Houghton et al., 2005). Mutations in EDAR represent the
autosomal ED locus located on chromosome 2q (OMIM 604095). This locus accounts for
one-quarter of all non-EDA-induced ED (Chassaing et al., 2006).
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EDAR intracellularly binds to EDARADD, an adapter molecule for EDAR.
EDARADD transmits the signal from the receptor to the downstream signaling proteins.
Mutations in EDARADD on chromosome 1q have been reported in patients with
autosomal ED (OMIM 606603). EDARADD is thought to function by recruiting a protein
complex that includes TAB2, TAK1, and TRAF6 (located at 11p; OMIM 602355) which,
when mutated in mice, results in ED (Naito et al., 2002; Morlon et al., 2005). TAK1 then
phosphorylates and activates IKK, which subsequently triggers the degradation of the IkB
regulatory subunit releasing active NF-kB, which then enters the nucleus to regulate
expression of EDA-A1’s target genes (Doffinger et al., 2001; Kumar et al., 2001).
The targets genes of the EDA pathway have only recently started to be identified.
So far, four pathways in particular appear to be targets of EDA. EDA signaling has been
shown to be the trigger for Sonic hedgehog (Shh) and cyclin D1 expression, which is critical
for continued hair follicle development after hair placode growth initiation (Schmidt-Ullrich
et al., 2006). Nishioka and co-workers identified that the structural proteins mucosal
addressin cell adhesion molecule 1 (MAdCAM-1) and intercellular adhesion molecule 1
(ICAM-1) play a role in the development of mouse guard hairs as targets of the EDA
signaling pathway (Nishioka et al., 2002). Lymphotoxin-N (LTN) was identified through
microarray experiments comparing the expression profiles of normal and Tabby mice. LTN
was previously known to only participate in lymphoid organogenesis, but has since been
shown to be critical for proper hair formation in mice (Cui et al., 2006). The Wnt agonists
Dkk1 and Dkk4 also appear to be targets of EDA signaling. Wnt up-regulates EDA
expression, subsequently up-regulating Dkk1 and Dkk4, which act as negative feedbacks to
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Wnt resulting in reduced EDA expression (Figure P.2) (Andl et al., 2002; Durmowicz et al.,
2002; Cui et al., 2006; Cui and Schlessinger, 2006).
There are many clinical phenotypes that have been associated with ED. Since
several of the EDA signaling pathway proteins have roles in other signaling pathways,
mutations in these pathway members can lead to complex phenotypes in addition to ED.
For example, mutations in inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
(IKBKG) at Xq28, which codes for NEMO (OMIM 300248), a regulator of NF-kB activity,
result in ED with immune deficiency (Doffinger et al., 2001; Smahi et al., 2002). More
frequently, however, ED and these associated clinical findings are linked to mutations in
genes whose role in ectodermal differentiation is unknown. Mutations in the tumor protein
p63, located at 3q27, result in split-hand/split-foot malformation, ectodermal dysplasia, and
facial clefts (OMIM 603273). Mutations in cadherin-3, located at 16q22.1, have been
identified in patients with ectodermal dysplasia, ectrodactyly associated with syndactyly or
cleft hand or both, and macular dystrophy (OMIM 225280). Missense mutations in the
GJB6 gene, which is located at 13q12 and encodes connexin-30, have been linked both to
ED and to autosomal dominant nonsyndromic sensorineural deafness 3 (Grifa et al., 1999;
Lamartine et al., 2000; Smith et al., 2002).
Another gene which has been linked to the ED phenotype but whose molecular role
in ectodermal development remains unclear is epidermal growth factor (EGF). Treatment of
wildtype mice with EGF results in premature eyelid opening and incisor eruption (Cohen,
1962; Kapalanga and Blecher, 1990). One portion of the tabby phenotype includes delayed
eyelid opening and incisor eruption (Kapalanga and Blecher, 1990). Prenatal injection of
EGF into tabby mice results in the correction of eyelid opening and incisor eruption timing
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(Kapalanga and Blecher, 1990; Kapalanga and Blecher, 1991). Treatment of skin cell culture
systems with EGF results in inhibition of hair follicle formation (Kashiwagi et al., 1997). In
vivo experiments in the marsupial Isoodon macrourus have also shown treatment with
exogenous EGF results in the inhibition of development of hair follicles, sweat glands,
sebaceous glands, and dermal papillae (Adelson et al., 1997). Furthermore, fibroblasts from
tabby mice and HED patients have been reported to have reduced levels of EGF’s receptor,
EGFR, both at the messenger RNA and protein level (Vargas et al., 1996; Cui et al., 2002).
The restoration of ta signaling through the transfection of tabby mice with an EDA-A1
transgene resulted in normal EGFR expression levels as compared to wildtype mice (Cui et
al., 2002). However, ectopic treatment of tabby mice with EGF did not correct the molar
cusp formation abnormalities, a portion of the tabby phenotype (Pispa et al., 1999).
Neurological clinical findings in the form of mental retardation (MR), can be
associated with the ED phenotype (OMIM 225060, 203550, 256710, 600644). The affected
gene or genes in these case reports are often not known. Linkage data likewise is not
available for most of these reports. These rare cases of ED and neurological findings led
many authors in the past to incorrectly surmise a link between HED and MR. This
assumption was supported by the fact that the original patients whose chromosomal
abnormalities were used to map the HED X locus were affected with MR in addition to their
ectodermal defects. It is now understood that the cognitive involvement seen in some of
these patients were likely due to other genes disrupted by chromosomal breakpoints.
Mental retardation is a significant developmental disorder affecting an estimated 23% of the world’s population. It can result from both environmental and genetic causes.
One South Carolina study cited genetic causes of MR at 23% of all cases and 63% of those
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for which the cause could be identified (Stevenson et al., 2003). The study found single gene
causes of MR could be identified in 8% of the patient cohort.
The most progress in identifying genes associated with MR has been made on the X
chromosome. The identification of X-linked families by pedigree followed by linkage
studies to identify X-linked mental retardation loci has proven to be an efficient method to
identify single gene causes of MR. More than eighty MR genes have been identified
(Stevenson, 2005).
It has been comparatively more difficult to identify single genes involved in
autosomal MR. If an X-linked inheritance pattern can be identified, linkage analysis needs
only to be done on the X chromosome. In the absence of an X-linked inheritance pattern,
the expense involved in performing linkage on the entire genome is restrictive. In addition,
finding families large enough to provide the statistical power necessary to do linkage analysis
is rare. Given these restrictions, the use of cytogenetically visible abnormalities to mark
regions on a particular chromosome where the causative gene resides, termed positional
cloning, is one method employed to identify autosomal MR genes. EDA was initially
identified also using positional cloning. In part because of these difficulties, only three
autosomal MR genes have been identified compared to the numerous XLMR genes
(Raymond and Tarpey, 2006).
This dissertation has attempted to investigate three areas related to ectodermal
dysplasia. First, the extracellular domains of EDA have been well documented; however,
there remain questions concerning the functional role of the intracellular N-terminal domain
(N-EDA). The inability to identify causatives mutations in all ED patients suggests
additional genes remain whose function in ectodermal differentiation has yet to be identified.
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Although many members of the EDA signaling pathway have been identified in recent years,
there remain chromosomal loci linked to ED but without causative genes identified.
Finally, MR is often a clinical phenotype associated with ED but is not directly linked to
genes in the EDA signaling pathway. This work attempts to identify the cause of the MR
seen in two patients with ED.
The first chapter of this work presents a functional characterization of EDA-1. We
have used a yeast 2-hybrid screen with N-EDA to identify the nuclear protein RBM39 as a
novel protein interactor. Fluorescence microscopy demonstrated N-EDA accumulates in
the cell nucleus at significantly higher levels than other cellular structures.
The second chapter presents work aimed at identifying novel candidate genes either
in the EDA signaling pathway or targets of it. A patient with a t(1;6)(p22.2;p22.2)
translocation presented with mild HED. We hypothesized that the translocation disrupted a
gene resulting in the HED. Physically mapped bacterial artificial chromosome (BAC) clones
which span both breakpoints have been identified and the minimal critical regions likely to
harbor candidate genes have been determined.
The final chapter presents work attempting to identify the cause of an associated
clinical feature in one patient with HED. This patient’s clinical features included HED and
MR. Her karyotype revealed a t(X;9)(q13;p24.3) translocation. The X breakpoint disrupts
the EDA gene resulting in HED. We hypothesized the chromosome 9 breakpoint affects a
gene resulting in the MR. Furthermore, an unrelated patient was also identified with a 9p
subtelomeric chromosome abnormality. We mapped those aberrations and identified and
characterized a gene, DOCK8, physically disrupted in both patients.
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In summary, this work presents the identification of a protein found to interact with
the intracellular domain of EDA, providing the first evidence of a functional role for the
intracellular domain. Additionally, two translocation breakpoint loci were partially mapped,
identifying novel candidate genes for both ED and MR. Finally, DOCK8 was identified as
the gene disrupted as a result of chromosomal aberrations in two patients, one with HED
and MR and the second with only MR, suggesting that DOCK8 could play a role in normal
brain development or function. These results add to the understanding of how ectodermally
derived structures form and explain the presence of the additional clinical phenotype MR
seen in many ED patients.
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FUNCTIONAL ANALYSIS OF THE N-TERMINAL INTRACELLULAR
FRAGMENT OF ECTODYSPLASIN-1
Introduction
Ectodermal dysplasia (ED) is a developmental disorder affecting ectodermally
derived structures such as hair, teeth, nails, and sweat glands. Mutations in either
ectodysplasin-A (EDA) or its downstream receptors can cause EDs (Kere et al., 1996;
Headon and Overbeek, 1999; Monreal et al., 1999). Identified in 1996, EDA is a type II
transmembrane protein whose expression is modulated by WNT and Lef1 (Kere et al., 1996;
Laurikkala et al., 2001; Laurikkala et al., 2002). Multiple isoforms of the protein have been
identified, some with varying expression patterns, suggesting possible roles for EDA in areas
other than ectodermal appendage development. Although varying in size and exon
composition, all of the isoforms share the N-terminal intracellular domain and the
transmembrane domain (Fig. P.1) (Kere et al., 1996; Bayes et al., 1998). The EDA-A1
isoform is required to initiate secondary differentiation of ectodermally derived structures.
The signaling cascade triggered by EDA-A1 has been previously reviewed (Fig. P.2) (Cui and
Schlessinger, 2006). On the cell membrane, EDA-A1 forms a homotrimer which is
subsequently cleaved by a serine-like furin protease allowing the C-terminal TNF homology
domain to become a soluble ligand (Ezer et al., 1999; Chen et al., 2001; Elomaa et al., 2001).
Upon binding to the EDA receptor (EDAR), a signaling cascade is initiated which results in
the activation of NF-kB leading to target gene expression (Elomaa et al., 2001; Laurikkala et
al., 2001). This signaling pathway has been extensively studied over the last decade;
however, there still remain several unanswered questions.
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One of the most obvious questions that remain is what function does the N-terminal
intracellular portion of EDA (N-EDA) have? Could this portion of the protein be involved
in trimer formation, thus allowing EDA to be cleaved? Alternately, this may have a role in
the remaining portion of the protein after cleavage of the extracellular portion. Since it is
present in all isoforms of the EDA protein, the identification of potential protein interactors
could shed light on additional, yet unknown, intracellular signaling in which EDA
participates. N-EDA has been previously studied by Mikkola and coworkers (1999), who
screened 3.2 x 106 clones with the intracellular domain (aa1-39) with a human keratinocyte
library using a LexA-based yeast 2-hybrid system, but only identified false positive clones.
These results suggest that either the N-EDA does not bind other proteins or that the
potential protein interactors were not present in the keratinocyte library. Binding partners
could be specific to a particular function of the protein and subsequently have a limited
temporal or spatial expression pattern. The possibility also exists that the N-EDA is utilized
by splice variants not involved in epidermal development.
This study has attempted to clarify the role of the N-terminal portion of the EDA
protein. Using a GAL4-based yeast 2-hybrid approach; RBM39 was identified in a human
fetal brain cDNA library using the N-terminal portion of EDA as bait. Transfection of a V5
epitope tagged N-Terminal EDA construct into COS-7 cells reveals an accumulation of NEDA in the nucleus, an observation previously not reported. The tagged N-EDA molecule
was also found to localize to the nucleus with RBM39. Together, these results suggest that
N-EDA interacts with RBM39 for an, as yet to be described, function.
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Materials and methods
Vectors
The vectors used in the yeast two-hybrid screen were obtained from Clontech
(Mountain View, CA) as a part of the Matchmaker™ two-hybrid system 3 kit. The bait
vector, pGBKT7, includes a kanamycin resistance gene for bacterial selection and a
tryptophan pathway (Trp) gene for selection in yeast. In addition, there is a c-myc epitope in
frame with the insert. pGBKT7 creates a fusion protein of the GAL4 DNA binding domain
(BD) and the inserted protein sequence. The pAS2.1 primer pair flanks the vector multicloning site (MCS) - pAS2.1 Forward 5’-tcatcggaagagagtagtaac -3’, Reverse 5’cgttttaaaacctaagagtcac-3’ (product size: 230 bp plus insert; annealing temperature 61oC). The
prey vector, pGADT7, includes an ampicillin resistance gene for bacterial selection and a
leucine pathway (Leu) gene for selection in yeast. There is an HA epitope in frame with the
insert. pGADT7 creates a fusion protein between the GAL4 activation domain (AD) and
the inserted protein sequence. The pACT2 primer pair flanks the vector MCS - pACT2
Forward 5’-ctattcgatgatgaagataccccacc -3’, Reverse 5’- gtgaacttgcggggtttttcagtatc-3’ (product
size: 210 bp plus insert; annealing temperature 64oC).
Mammalian expression vectors used in the co-localization studies were obtained
from Invitrogen (Carlsbad, CA). N-EDA was inserted into pcDNA3.1D/V5-His-TOPO®.
The PC / BGH primer pair flanked the vector MCS – PC Forward 5’-gggagacccaagctggctagt
-3’, BGH Reverse 5’-tagaaggcacagtcgag -3’ (product size: 250 bp plus insert; annealing
temperature 60oC). RBM39 (clone 4.18) was inserted into pcDNA3.1/NT-GFP-TOPO®.
The GFP forward primer was used with the BGH reverse primer to flank the vector MCS –
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GFP Forward 5’-cacaatctgccctttcgaaa -3’ (product size: 271 bp plus insert; annealing
temperature 60oC). Both vectors utilize ampicillin resistance for selection in bacteria.

N-EDA Construct
The intracellular portion of EDA (N-EDA) had previously been cloned into the
pAS2.1 yeast two-hybrid bait vector (Hartung and Srivastava, unpublished). This construct
was used as the template for creating the pGBKT7+ N-EDA construct used in the library
screen. Restriction endonuclease recognition sites that would allow for excision of the NEDA insert followed by subsequent ligation of the insert in the correct reading frame into
the pGBKT7 vector were identified in pAS2.1+N-EDA. Eight Rg of pAS2.1+N-EDA and
three Rg of pGBKT7 were digested with BamHI and NcoI (New England Biolabs, Ipswich,
MA) in NEB buffer 3 at 37°C for 12 hours. Digests were resolved on a 1% TAE agarose
gel, extracted from the gel, and purified with the QIAquick Gel Extraction Kit (QIAGEN,
Valencia, CA) following the manufacturer’s protocols. Ligation reactions were then set up at
a 3:1 (insert/vector) 0.002 pmole ratio using T4 ligase and buffer (Invitrogen). Ligation
reactions were incubated overnight at 14°C. Ligation products were transformed into One
Shot® Top10 chemically competent bacteria (Invitrogen). Transformants were screened
through colony PCR to identify positive clones. The bacterial colonies were suspended in 50
Rl sterile distilled H2O. Two Rl from each colony was then added to a gridded LB/Kan agar
plate for later isolation. An additional two Rl of the suspended bacteria were then used as
template in a colony PCR. Plasmid preparations were made of the positive clones and then
sequenced to verify insert integrity and reading frame.
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Yeast strains
The AH109 yeast strain (Clontech) was used for the library screen and subsequent
yeast mating experiments. AH109 provides four reporter genes to test for protein-protein
interactions: ADE2, HIS3, lacZ, and MEL1. The Y187 yeast strain (Clontech) was used in
the yeast mating experiments. Y187 provides three reporter genes to test for protein-protein
interactions: ADE2, HIS3, and lacZ.

Bacterial Culture and Plasmid Preparations
Bacterial clones were grown on LB agar plates with appropriate antibiotic selection at
37°C for 16-18 hours, except where noted. Bacterial clones were grown in liquid culture at
37°C shaking at 250 rpm for 16-18 hours.
Plasmid isolations were performed using one of three methods. Standard
preparations were isolated with the QIAprep Spin Miniprep kit (QIAGEN). Preparations
used in COS-7 transfections were prepared using the PureYield™ plasmid midiprep system
(Promega). Library scale isolations were performed using the QIAGEN Plasmid Giga Kit
(QIAGEN).

Bacterial Transformations
One Shot® Top10 chemically competent bacteria cells (Invitrogen) were thawed on
ice for 5 minutes. DNA (<25 ng) was added to the bacteria, followed by a 30 minute
incubation on ice. The bacteria cells were then heat shocked at 42°C for 35 seconds and
returned to ice. 250 Rl of SOC media (Invitrogen) was added to the heat shocked cells,
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followed by an one hour incubation at 37°C. The bacteria cells were then plated on
LB/Kanamycin (50 Rg/ml) agar plates.

Yeast Culture and Plasmid Preparations
Protocols for yeast strain maintenance and media composition were obtained from
the Yeast Protocols Handbook (Clontech). Yeast strains were maintained on yeast extract,
BactoPeptone, dextrose, and adenine media (YPDA). Components for nutritional selective
medias were purchased from Contech. Selective media was made by adding to the yeast
nitrogen base media mix the appropriate amino acid dropout combination. –Trp media
contained all amino acids except tryptophan and was used when selecting only for the
pGBKT7 vector. –Leu dropout media contained all amino acids except leucine and was
used when selecting only for the pGADT7 vector. –Leu,Trp selective media was used for
yeast transformed with both the pGBKT7 and pGADT7 vectors. Adenine (Ade) and
histidine (His) were the two nutritional reporter genes in both yeast strains. -Ade,His,
Leu,Trp media provided selection pressure for both vectors in addition to selecting for those
transformants who were positive for a bait protein and prey protein interaction. In addition
to the nutritional selection, V-gal (Clontech) could be applied to –Ade,His,Leu,Trp plates.
An active MEL1 reporter gene transcribes V-galactosidase which breaks the V-gal down
resulting in blue colonies.
Yeast were grown on agar plates at 30°C for 3-5 days, or until colonies 0.2 mm in
diameter appeared. Yeast were grown in liquid culture at 30°C shaking at 250 rpm for 16-18
hours or as specified.
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Plasmids were isolated from fresh overnight cultures using the Zymoprep II™ Yeast
Plasmid Minipreparation Kit (Zymo Research).

Yeast Transformations
Yeast strains were transformed using the Polyethylene glycol (PEG)/ Lithium acetate
(LiAc) method outlined in the Yeast Protocols Handbook (Clontech). A single yeast colony
(either AH109 or Y187) was inoculated in 50 ml of YPDA or appropriate selective media
and grown 18 hours at 30°C with shaking. Approximately 30 ml (or enough to produce a
final O.D.600=0.2-0.3) was then added to 300 ml of YPDA. The yeast were incubated at
30°C with shaking for 3 hours or until the O.D.600 was approximately equal to 0.5. The yeast
were collected, washed with sdH2O, and resuspended in 1.5 ml of 1xTE/LiAc (10x TE: 0.1
M Tris-HCl, 10 mM EDTA, pH 7.5; 10x LiAc: 1 M lithium acetate, pH 7.5).
Transformations were performed in a 1.5 ml tube by combining DNA (0.1 Rg in single
transformation, 5 Rg in library transformations), 0.1 mg Herring testes carrier DNA
(Clontech), 0.1 ml competent yeast, and 0.6 ml PEG/LiAc (40% PEG 4000, 1x TE, 1x
LiAc). The yeast were incubated at 30°C for 30 minutes followed by the addition of 70 Rl
DMSO. Next, the yeast were heat shocked at 30°C for 15 minutes and returned to ice.
Finally, the yeast were collected from the transformation cocktail by centrifugation and
resuspended in YPDA and were allowed to recover in YPDA for 1 hour at 30°C followed by
plating on appropriate selective plates.
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Yeast Plasmid Preparations
Fresh yeast colonies were grown overnight in 5 ml of appropriate media. Plasmids
were isolated using the Zymoprep II™ Yeast Plasmid Minipreparation Kit (Zymo Research,
Orange, CA).

Yeast Mating
Yeast mating was performed by first transforming a bait and prey vector into AH109
and Y187 respectively. A single transformed colony was then suspended in 100 Rl YPDA.
A bait and prey clone were then mixed together and incubated at 30°C for 18 hours. Yeast
were collected by centrifugation, washed with 1xTE, and plated onto –Leu,Trp or –Ade,His,
Leu,Trp plates.

Sequencing
PCR amplicons were generated using the pAS2.1 vector primers. The PCR products
were purified with GFX™ PCR Purification Kit (GE Healthcare) using manufacturer’s
protocols. A dideoxy terminator sequencing reaction was set up using fifty nanograms of
the purified PCR product and the DYEnamic™ ET dye terminator kit (GE Healthcare,
Piscataway, NJ) following manufacturer’s guidelines. Sequencing was performed on a
MegaBACE 1000 (GE Healthcare). Sequences were analyzed using the Lasergene software
package (DNASTAR, Inc., Madison, WI)
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Autoactivation Assay
All yeast constructs were interacted against empty vectors and a non-specific protein
to ensure the construct was not capable of activating the reporter genes in the absence of a
true interacting protein. Constructs were transformed into AH109 with the appropriate
control and plated on –Leu,Trp and –Ade,His,Leu,Trp plates. Growth on the –Ade,His,
Leu,Trp plates identified that clone as a false positive.

Library Amplification
The Human Fetal Brain Matchmacker™ cDNA Library (Clontech) was used for the
yeast two-hybrid screen. The cDNA library was originally created from mRNA obtained
from nine pooled 20-25 week human fetuses. The library vector was pAS2.1, the prey
vector from the Clontech Matchmaker™ two-hybrid system 2.
The library was amplified to provide three-fold coverage to the 3.5x106 independent
library clones present. Amplification of the library was performed following the
manufacturer’s protocol.

The clones were plated on LB/amp plates at a concentration of

40,000 clones per 115 mm plate. The plates were incubated at 30°C for 36-40 hours. The
clones were collected in 5 ml LB by scraping. Plasmid preparations were prepared using the
QIAGEN Plasmid Giga Kit following manufacturer’s protocols.

Yeast 2-Hybrid Screen
AH109 yeast were transformed with the pGBKT7+N-EDA construct using the
LiCl/PEG method. Transformants were selected on –T plates. Transformed clones were
isolated and used for plasmid DNA preparations. Plasmids were transformed into One
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Shot® cells (Invitrogen) and grown on the appropriate antibiotic selection LB plate.
Plasmid preparations were made from the transformed bacteria and sequenced.
pGBKT7+N-EDA containing yeast clones were then transformed with the Human Fetal
Brain cDNA library (Clontech) as described previously. Transformants were plated on high
stringency -Ade,His,Leu,Trp selective plates. A portion of the transformation was plated on
-Leu,Trp plates to calculate transformation efficiency. Clones that grew in the initial plating
of the library transformants onto -Ade,His,Leu,Trp plates were selected and re-plated on Ade,His,Leu,Trp to further select for true positives. Positive clones were grown overnight
in a 5ml culture followed by plasmid preparations. Isolated plasmids were transformed into
One Shot™ cells (Invitrogen). Bacterial plasmid preps were then sequenced to identify
clones. Sequence information was submitted to a BLAST search to identify the insert.
Clone inserts that were not coding for known genes or representing non-coding or
untranslated regions of known genes were eliminated. All clones coding for known proteins
were then tested for autoactivation by interacting them with empty bait plasmids and the
false positive pLAM5’ bait plasmids. Clones that showed no autoactivation were again
interacted using yeast mating with the AH109 and Y187 yeast strains. The clones were
transformed into the Y187 cell line and mated to AH109 yeast previously transformed with
the pGBKT7+N-EDA construct.

Vector Swap
The N-EDA insert in pGBKT7 and the RBM39 clone 4-18 were amplified using
adapter primers (Table 1.1). The PCR products were subcloned in the pCR2.1 vector
(Invitrogen) and sequenced. Bacterial preps of these vectors were then digested with NdeI
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and EcoRI (N-EDA) or SmaI and SalI (RBM39), followed by gel isolation and ligation into
either pGBKT7 (RBM39) or pGADT7 (N-EDA). These constructs were again sequenced
to ensure proper reading frame and transformed into AH109 as previously described.

Table 1.1 Primer List
Primer Name
N-EDA VS
F/R
RBM39 VS2
F/R
pACT2 T7 coip F/R
N-EDA
ORF+Kozak
F/R
RBM39cnst2N
F/R

Annealing
Temperature
(°C)

Amplicon
Size (bp)

Vector Swap

68

129

Vector Swap

60

673

Addition of T7
promoter to pACT2
vector

72

varies

gctgttcccttcgcccgcccgggc

Co-localization
construct

55

121

aatggatttgaactagcaggaaga
tcatcgtctacttggaaccagtag

Co-localization
construct

72

663

Sequence (5’-3’)

Used For

catatgatgggctacccggaggtg
gaattcgctgttcccttcgcccgc
cccggggaatggatttgaactagca
gtcgactcatcgtctacttggaac
aaaattgtaatacgactcactatagggcgagccgccaccatgtacccatacgatgttccagattacgct
acttggggggtttttcagtatctacg
caccatgggctacccggaggtggag

In vitro Co-Immunoprecipitation
Protein-protein interactions were verified using the Matchmaker™ Co-IP kit
(Clontech). Primers were created to add a T7 promoter site to the RBM39 clone 4-18
plasmid (Table 1.1). The resulting PCR product was used as template for an in vitro
transcription/translation (Promega, Madison, WI) reaction to incorporate 35S-methionine
into the product. Control and bait plasmids already contained the T7 promoter and were
used directly in the in vitro transcription/translation. 10 ul of each in vitro
transcription/translation product was mixed at room temperature for 1 hour. The HA
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epitope antibody was added and incubated for 1 hour at room temperature. Protein A beads
were pretreated in Phosphate buffered saline (PBS) with 2.5% BSA. The protein A beads
were then used to pull the HA antibody bound proteins out of solution. Washes were
performed using solutions from the Matchmaker Co-IP kit. The resulting protein was
resolved on a 15% SDS/PAGE gel, transferred to a nitrocellulose membrane with a BioRad
Trans-blot® Semi-Dry Transfer Cell, and exposed to BioMax film (Kodak, Rochester, NY).

Fluorescence Microscopy Constructs
To determine cellular localization, N-EDA and RBM39 (clone 4-18) were cloned
into pCR3.1 TOPO family expression vectors (Invitrogen) following manufacture’s
protocols.

The vectors utilized a topoisomerase mitigated ligation for the incorporation of

insert sequences. Primers were designed to amplify the inserts of interest (Table 1.1). The
pGBKT7+N-EDA and the RBM39 (4-18) constructs were used as templates for these
reactions. N-EDA was cloned into pCR3.1 TOPO v5/His. The portion of RBM39
represented by clone 4-18 was ligated into pCR3.1 NGFP. These constructs were sequenced
to ensure proper reading frame.

Mammalian Cell Culture
COS-7 cell line was cultured using standard protocols. In brief, the cells were grown
in Dulbecco's Modified Eagle Media (DMEM) with 4 mM L-glutamine adjusted to contain
1.5 g/L sodium bicarbonate and 4.5 g/L glucose (Sigma, St. Louis, MO). The media was
completed by the addition of fetal bovine serum to 10%. The cells were grown at 37°C with
10% CO2.
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The cells were passaged when they approached 90% confluence. The growth media
was removed and the cells were washed 2 times with PBS. Trypsin+EDTA (Sigma) was
added briefly to the cells and removed. The cells were incubated at 37°C for 10 minutes,
followed by collection with complete DMEM.

Mammalian Cell Transfections
Sub-confluent COS-7 cells were seeded at a density of 50,000 cells in plating media
(DMEM with 1% FBS) onto Poly-lysine (Sigma) treated glass cover slips in 12-well cell
culture dishes (Falcon, Branchburg, NJ). Cells were transfected with 0.8 Rg of the
appropriate vector with the Lipofectamine 2000 (Invitrogen) transfection reagents at a ratio
of 1:2 (DNA: Lipofectamine). The transfection mix was applied to the cells for 5 hours,
after which the cells were washed in (PBS) and grown for 48 hours in normal growth media.

Fluorescence Microscopy
Transfected COS-7 cells were stained with anti-V5 mouse monoclonal antibody
(Invitrogen) to visualize N-EDA or EDA-A1. The anti-Lamin B goat polyclonal antibody
(Santa Cruz, Santa Cruz, CA) was used to stain the nuclear membrane. To facilitate its
detection, RBM39 was expressed as a fusion with green fluorescence protein (GFP) at its Nterminus.
The Anti-V5 mouse monoclonal antibody was visualized though conjugation with
Alexa Flour® 594 goat anti-mouse (Invitrogen). The Anti-Lamin B goat polyclonal antibody
was detected by using Alexa Fluor® 647 chicken anti-goat. The cells transfected with only
N-EDA or RBM39 were also stained with Alexa Fluor® 488 phalloidin green (N-EDA) or
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Alexa Fluor® 594 phalloidin red (RBM39) to visualize the actin cytoskeleton. Cells were
washed two times with PBS and fixed with 4% para-formaldehyde for 5 minutes. Cells were
then permeabilized with 0.1% Triton X-100 in PBS for 5 minutes, and washed twice with
PBS. The cells were then incubated with a quenching solution (1.02 g sodium acetate in 50
ml PBS) twice for 8 minutes each to decrease fluorescence background of paraformaldehyde. Cells were then incubated for 30 minutes in a blocking solution (2% horse
sera, 0.4% BSA in PBS). Primary antibodies were diluted 1:400 in the blocking solution and
applied to the cells for 1 hour at room temperature. Cells were rinsed three times (5 minutes
per wash) with Blocking solution followed by a final rinse in TS (10 mM Tris-HCl pH 7.5,
15 mM NaCl). Secondary antibodies diluted 1:2000 in Blocking solution were then added to
the cells. The cells were then rinsed four times with PBS and coverslips were mounted onto
microscope slides using Anit-Fade Gold (Invitrogen). Fluorescence microscopy was
performed using a Zeiss LSM510 fitted with image analysis software.

Results
Identification of N-EDA Protein Interactors
The intracellular domain of EDA is encoded by amino acids 1-39. The
pGBKT7+N-EDA plasmid expressing a fusion protein comprised of the GAL4 DNA
binding domain and EDA intracellular domain was interacted against the pACT2 human
fetal brain library to identify novel protein interactors. Approximately 936,000 clones were
screened. A positive interacting clone was expected to grow on -Ade,His,Leu,Trp plates due
to the presence of a bait plasmid containing a Trp nutrient marker and a prey plasmid that
contains a Leu nutrient marker. Additionally, a protein – protein interaction between the
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bait and prey constructs results in the activation of the Ade and His nutrient marker reporter
genes and the V-galactosidase color reporter gene. Seventy-two clones grew on Ade,His,Leu,Trp selective plates, suggesting an interaction between the GAL4-N-EDA
protein and the proteins encoded by those individual clones of the cDNA library. The
activation of a third reporter gene in the AH109 yeast strain, MEL1, was then tested through
V-galactosidase activity. The yeast clones were plated on -Ade,His,Leu,Trp + V-gal [20
ng/ml] plates. Of the 72 original positive clones, 60 clones were found to have positive Vgalactosidase activity demonstrated by the colony turning blue, indicating a likely interaction
between N-EDA and the protein coded for by the gene present in the fetal brain library.
The prey vectors containing the cDNA library inserts were then isolated and sequenced.
After identifying duplicate clones based on sequence, 37 unique clones remained. Of these,
only 21 were found to code for proteins. The remaining clones inserts were found to either
represent untranslated regions of genes or non-genic sequences. The 21 remaining clones
were individually co-transformed into AH109 with pGBKT7 or pLAM5’-1, coding for the 5’
portion of the lamin C gene as a putative negative control. The reporter genes were activated
in all but two of these transformants, eliminating 19 as false positives.
One of the positive clones was C17ORF32 (MGC45714). When transformed with
pGBKT7 or pLAM5’-1, several slow growing light blue colonies resulted suggesting a weak
interaction between the C17ORF32 clone and the negative control plasmids. C17ORF32
was not dismissed as a false positive because, when transformed with pGBKT7+N-EDA,
the resulting clones were robust, both in growth and color selection. This suggests the NEDA – C17ORF32 interaction was stronger than the background level seen in the negative
controls. This clone subsequently failed to produce a product in in vitro transcription/
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translation reactions and may yet be a false positive. Characterization of this clone is on
going.
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Figure 1.1 Yeast 2-hybrid positive clone, vector swap clone, and false positive controls. (1)
Positive control (2) N-EDA + RBM39 vector swap (3) N-EDA + Clone 4-18 (4) pGBKT753 + 4.18 (5) pGBKT7 + 4.18 (6) N-EDA + pGADT7-T (7) N-EDA + pGADT7 (8)
Negative control. pGBKT7 + N-EDA interacted with pAS2.1 + 4-18 and the vector swap
with pGBKT7 + 4-18 interacted with pGADT7 + N-EDA both show protein-protein
interaction through activation of the reporter genes. Reduced growth and lighter blue
colonies in 2 and 3 as compared to the positive control in 1 suggests that the N-EDA +
RBM39 interaction is weak as compared to the strong interaction seen in the positive
control. Absence of growth on selective media for the N-EDA and the RBM39 negative
controls suggest the activation of the reporter genes in 2 and 3 is the result of an interaction
between N-EDA and RBM39 and not the result of a non-specific interaction. Growth of all
clones on the -Leu,Trp plates show each yeast transformant was viable.

The other gene identified in the two-hybrid screen was RBM39 (Fig. 1.1 and 1.2).
Two different library transformants, 4-18 and 4-38, were found to code for this protein.
Specifically, both clones 4-18 and 4-38 were found to code for RBM39 isoform a. Clone 418 coded for RBM39 isoform a amino acids 312-530 (Fig. 1.2a). Clone 4-38 coded for
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RBM39 isoform a amino acids 96-530, overlapping and completely including the coding
region present in clone 4-18 (Fig. 1.2a). RBM39 isoform b lacks 6 amino acids (a.a 392-397)
coded for in RBM39 isoform a and by clones 4-18 and 4-38. RBM39 isoforms c, d, and e
have also been identified but are nonsense-mediated mRNA decay (NMD) candidates
(GenBank NM_184241.1, NM_184244.1, and NM_184237.1). Additionally, isoforms c, d,
and e code for 78 bp in the 5’ region of RBM39 not present in isoforms a and b or clones 418 and 4-38.
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Figure 1.2 RBM39 genomic and protein alignments. (a) The genomic structure of RBM39
is indicated. The gene codes for five splice variants, three of which are targets of nonsense
mediated decay. The two splice variants which code for proteins are shown. The portions
of RBM39 coded for by clones 4-18 and 4-38 are indicated. (b) The RBM39 protein consists
of 3 RNA recognition motifs (RRM) and a serine rich (SR) region, and the exons coding for
these domains are indicated. The portion RBM39 coded for by clones 4-38 and 4-18 is
indicated by blue bars.
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Clone 4-18 was further tested to verify that the activation of the reporter genes was
the result of a specific interaction between N-EDA and RBM39. The first step was to
perform a yeast mating assay to serve as an independent verification of the results seen in the
co-transformation experiments. The pGBKT7+N-EDA construct was transformed into the
AH109 yeast strain and clone 4-18 was transformed into the Y187 yeast strain. The yeast
were allowed to mate overnight and subsequently plated onto –AHLT selective plates.
pGBKT7+N-EDA and clone 4-18 mated yeast grew on selective plates whereas yeast
transformed with controls to check for nonspecific activation of the reporter genes did not
grow on selective plates.
A final in vivo experiment was performed to support the protein interaction between
N-EDA and RBM39. To ensure that the positive interaction was not the result of the
specific fusion proteins GAL4 BD + N-EDA and GAL4 AD +4-18, a vector swap assay
was performed. The N-EDA construct was moved to the prey vector pGADT7, resulting in
a GAL4 AD + N-EDA fusion protein, and the RBM39 4-18 construct was cloned into the
pGBKT7 vector, resulting in a GAL4BD + RBM39 4-18 fusion protein. Cotransformation of these constructs into AH109 yeast resulted in the activation of both the A
and H nutritional selection genes and the MEL color selection gene. As seen in Figure 1.1,
the vector swap yeast grew in a similar manner to that of the original N-EDA/4-18
transformant. The in vivo results seen in the yeast strongly support a protein-protein
interaction between N-EDA and RBM39. The interaction between N-EDA and RBM39 is a
weak interaction based on the growth and the intensity of blue colony color seen in these
transformants as compared to the positive control yeast colonies (Fig. 1.1).
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RBM39 is a nuclear protein which binds several types of transcription factors
including c-Jun and ERV and ERN and is a transcriptional co-activator of estrogen receptors
(Lee et al., 1999; Jung et al., 2002). RBM39 has three RNA recognition motifs (RRM) and a
serine rich region (Figure 1.2b). Clone 4-38 spans all of the RRMs while clone 4-18 spans
only the RRM nearest the carboxyl terminus of the protein (Fig.1.2b).

Verification of N-EDA and RBM39 Interaction Through Co-immunoprecipitation
In vitro transcription/translation products incorporating 35S-methionine were
generated in order to determine if N-EDA and RBM39 would co-immunoprecipitate. If
positive, this in vitro analysis would further support the N-EDA – RBM39 interaction. As
seen in Figure 1.3 lane 1, N-EDA precipitated with RBM39 using the c-Myc monoclonal
antibody. N-EDA could not be visualized in complementary pull-down assays using the HA
epitope tagged to RBM39 (Fig. 1.3, lane 2). The N-EDA protein is small (39 amino acids)
and only incorporates two 35S-methionines. Therefore, the lack of signal seen when
precipitating EDA with RBM39 and anti-HA is likely the combined results of a weak
protein-protein interaction between N-EDA and RBM39 as seen in the in vivo results
(Fig.1.1) and the relatively low signal strength of only two 35S-methionines incorporated into
the N-EDA protein. Controls verified neither the N-EDA nor RBM39 bound nonspecifically to the wrong antibody (Fig. 1.3, lanes 3 and 4). Attempts to precipitate nonspecific proteins (SV40 large T-antigen with N-EDA and Murine p53 with RBM39) were
also unsuccessful; suggesting the interaction seen between N-EDA and RBM39 is specific
(Fig. 1.3, lanes 5 and 6).
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Figure 1.3 Co-immunoprecipitation of N-EDA and RBM39 clone 4-18. In vitro
transcription / translation products and Co-IP reactions were resolved through SDS-PAGE.
(Lane 1) N-EDA and the c-Myc antibody pulled-down RBM39. (Lane 2) N-EDA could
not be visualized after pull-downs with RBM39 and the HA antibody. (Lane 3) RBM39 did
not precipitate with the c-Myc antibody. (Lane 4) N-EDA did not precipitate with the HA
antibody. (Lane 5) SV40 large T-antigen coded for by pGADT7-T did not precipitate with
N-EDA and the c-Myc antibody. (Lane 6) Murine p53 coded for by pGBKT7-53 did not
precipitate with RBM39 and the HA antibody.
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Cellular Localization of N-EDA and RBM39
RBM39 is a nuclear protein and EDA is a transmembrane protein (Ezer et al., 1997;
Lee et al., 1999). Previous studies have noted that the smaller EDA gene isoforms, in
particular EDA-O, appear to be perinuclear, but no study has demonstrated any EDA
isoform localizing to the nucleus (Ezer et al., 1999). Since RBM39 is primarily nuclear, this
raised the question as to whether or not the N-EDA+RBM39 interaction discovered
through the yeast two-hybrid system was biologically relevant or not. To help address this
question, expression constructs were made which tagged N-EDA with the V5 epitope and
RBM39 with a GFP fusion protein. Transfection into COS-7 cells revealed the N-EDA
construct actively localized to the nucleus (Figure 1.4a). Additionally, the RBM39 construct
was also found in the nucleus (Figure 1.4b), as has been previously reported (Imai et al.,
1993). In the present study, there was a significant amount of RBM39 found in the
cytoplasm (Fig. 1.4b and c). This is not surprising given the construct used only codes for
the 4-18 clone representing the C-terminal portion of the RBM39 protein. The lack of a
nuclear localization signal within N-EDA suggests that it is actively transported to the
nucleus. It remains to be determined if RBM39 is the facilitator of N-EDA’s nuclear
localization.
Co-transfection with both N-EDA and RBM39 expression constructs support the
single transfection findings that both proteins localize to the nucleus. Interestingly, there
was one region within the nucleus where RBM39 was excluded and N-EDA was
concentrated (Figure 1.4c). The identity of this region will be the focus of future studies.
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Figure 1.4 Cellular localization of N-EDA and RBM39. (a) N-EDA (red) localizes to
the nucleus (blue) of Cos-7 cells. The cellular outline is depicted by phalloidin staining
of actin (green). (b) RBM39 (green) localizes primarily to the nucleus, but is also found
in the cytoplasm. (c) Co-localization of N-EDA and RBM39. N-EDA is shown in red
in pane 1 and white in pane 2. Lamin B is shown in blue in pane 1 and white in pane 3.
RBM39 is shown in green in pane 1 and white in pane 4.
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Discussion
This work presents the findings that the N-terminal domain of EDA selected the
nuclear protein RBM39 in a yeast two-hybrid screen. Both in vivo and in vitro control
experiments support this interaction. N-EDA and RBM39 were found to both localize to
the nucleus.
RBM39 maps to 20q11.22. No ED locus has been mapped to this autosomal region.
This would mean that, either ED mutations in this gene have not been documented, or
interaction between RBM39 and N-EDA may represent a novel function of the EDA gene.
RBM39 was originally isolated through its interaction with other transcriptional activators in
the c-Jun pathway (Jung et al, 2002). Transcriptional activation in RBM39 appears to be
coupled to pre-mRNA splicing (Dowhan et al., 2005). RBM39 has been shown to interact
with core proteins in the spliceosome.
The identification of RBM39 as a possible interacting protein with the N-terminal
portion of EDA is a novel and unexpected finding. The interaction with N-EDA could
suggest a mechanism whereby the intracellular domain could be cleaved off, translocates to
the nucleus, and, finally affect gene expression of EDA-1 or other genes. A similar
mechanism exists with portions of the intracellular region of amyloid precursor protein
(APP). After cleavage by a \-secretase, the APP cytoplasmic fraction is rapidly degraded, but
translates to the nucleus, where it is thought to have signaling functions with Notch and
SREBP (Cupers et. al., 2001). A similar process could exist with the N-terminal portion of
the EDA protein.
Clones 4-18 and 4-38 code for portions of RBM39 which encompass RRMs,
otherwise known as a ribonucleoprotein domain. The RRM domain was first identified
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through its ability to bind mRNA precursors, however, it has since been shown to bind a
wide variety of proteins, as well (Shamoo et.al., 1995; Maris et. al., 2005). The RRM located
closest to the carboxyl terminus of RBM39 has been shown to interact with and activate
estrogen receptor (ER) transcription factors (Jung et. al., 2002). If the interaction between
N-EDA and RBM39 holds true, then N-EDA will be linked through RBM39 to ERs, which
are expressed in skin and have been shown to impact hair growth (Thornton, 2002).
It should be noted that the interaction found through the yeast two-hybrid screen
may not be biologically significant. Interaction between RBM39 and N-EDA is weak in vivo
and was difficult to resolve in co-immunoprecipitation assays. Also, there are no known
isoforms of EDA that consist only of the intracellular domain or that localize to the nucleus.
There is also no evidence that the intracellular domain is cleaved or internalized. Future
experiments including in vivo co-immunoprecipitation assays from COS-7 cells should help
resolve this question. The observation clearly shows that N-EDA accumulates in the
nucleus and in the surrounding cellular compartments.
In conclusion, this study has identified, through a yeast two-hybrid screen, a novel
interaction between the intracellular domain of EDA and RBM39. N-EDA appears to be
actively transported to the nucleus, where it co-localizes with RBM39 in some areas, it was
also found to concentrate in a region where RBM39 was excluded. Future experiments
should help determine if this is a biologically significant interaction.
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IDENTIFICATION OF CANDIDATE GENES FOR ECTODERMAL DYSPLASIA
AND AUTOSOMAL MR IN A PATIENT WITH A t(1;6)(p22.1;p22.2)
TRANSLOCATION
Introduction
Ectodermal dysplasia (ED) is a heterogeneous developmental disorder affecting the
secondary differentiation of ectodermally derived structures. The disease results in thin hair,
missing or abnormally shaped teeth, and a reduction in number of sweat glands. The
symptoms of the disease can be managed through orthodontics to correct misshapen teeth
and the limiting of physical activity to compensate for a reduced ability to shed excess heat
from the body through sweating. However, if ED is not diagnosed early, there is a
significant increase in mortality resulting from hyperthermia and respiratory tract infections
(Mikkola and Thesleff, 2003).
The molecule that initiates secondary differentiation of ectodermally derived
structures has been identified as the ectodysplasin-1 (EDA) gene (Kere et al., 1996). This
soluble tumor necrosis factor (TNF) ligand binds to the EDA receptor, triggering a signaling
cascade through NF-kB to activate target gene expression (Fig. P.2) (Ezer et al., 1999;
Headon and Overbeek, 1999; Doffinger et al., 2001). The EDA signaling pathway has been
well established, but work is now just beginning to identify genes that are the targets of this
pathway. EDA signaling has been shown to be the trigger for Sonic hedgehog (Shh) and
cyclin D1 expression, which is critical for continued hair follicle development after hair
placode growth initiation(Schmidt-Ullrich et al., 2006). The structural proteins mucosal
addressin cell adhesion molecule 1 (MAdCAM-1) and intercellular adhesion molecule 1
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(ICAM-1) play a role in the development of mouse guard hairs as a targets of the EDA
signaling pathway (Nishioka et al., 2002). Lymphotoxin-N (LTN) is critical for proper hair
formation in mice (Cui et al., 2006). The Wnt agonists Dkk1 and Dkk4 also appear to be
targets of EDA signaling. Wnt up-regulates EDA expression, subsequently up-regulating
Dkk1 and Dkk4, which then act as negative feedbacks to Wnt, resulting in reduced EDA
expression (Figure P.2) (Andl et al., 2002; Durmowicz et al., 2002; Cui et al., 2006; Cui and
Schlessinger, 2006).
The genes responsible for a large number of EDs and associated disorders are yet to
be identified. One way to identify these genes is to use a mapping approach utilizing
cytogenetically visible chromosomal aberrations in patients with ectodermal defects.
A patient has recently been reported with a mild HED phenotype and cytogenetic
findings of a t(1;6)(p22.1;p22.2) translocation (Asamoah et al., 2003). There are no known
HED genes located at either translocation locus. In this study, the chromosomal
breakpoints at 1p22.1 and 6p22.2 have been partially mapped and the candidate genes from
these regions have been identified. Expression levels of candidate genes expressed in the
lymphoblastoid cell lines available were analyzed. It is speculated that one of the genes
identified in this study may be affected by the translocation resulting in the patient’s clinical
features.

Materials and methods
Case report
CMS8770 has previously been described (Asamoah et al., 2003). In brief, this female
patient was born at 37 weeks to non-consanguineous parents after an uncomplicated
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pregnancy. The newborn period was also uncomplicated. Most early milestones were met;
however, she did not speak any words at 24 months of age. IQ results at 6.5 years of age
revealed she was borderline mild MR with a Full Scale IQ of 73. Dental evaluation during
this time revealed the absence of several permanent teeth. Subsequent evaluation revealed
poor hair and nail, growth as well as decreased sweating. The patients karyotype was
determined to be 46,XX,t(1;6)(p22.1;p22.2) de novo. Family history was only significant for
learning problems in two paternal uncles, one paternal aunt, and several paternal cousins.

Molecular cytogenetics
Genomic contigs, clones, markers, mapping and sequence information were obtained
from the NCBI (http://www.ncbi.nlm.nih.gov/genome/guide/human) databases. BAC and
PAC clones were obtained from commercial resources. DNA was isolated using Qiagen
Mini-Prep columns and was labeled by incorporation of digoxigenin-11-dUTP or biotin-16dUTP (Boehringer Mannheim) by nick translation using DNA polymerase (Life
Technologies). Labeled products were combined with a 50x human Cot-1 DNA (GibcoBRL) and the chromosome-specific labeled centromeric alphoid probe to a final
concentration of 20 ng/Rl in Hybrisol VII. Probes were denatured at 76oC for 10 minutes
and preassociated at 37 oC for 15-20 minutes before hybridization.
For in situ hybridization, the metaphase chromosome spreads were obtained from
lymphoblastoid cells using conventional methods. Slides were incubated in 2x SSC at 37oC
for 30 minutes, serially dehydrated in 70%, 80%, and 95% ethanol at room temperature,
denatured in 70% formamide/2 x SSC at 72oC for two minutes, then serially dehydrated in
70%, 80%, and 95% ethanol. In situ hybridization and washing procedures were performed
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as previously described (Ross et al., 1997; Vervoort et al., 2002). Replication banding was
performed simultaneously with FISH. Commercially available chromosome-specific labeled
centromeric alphoid probes were used to identify specific chromosomes. The labeled probes
were visualized with rhodamine-labeled anti-digoxigenin, and chromosomes were
counterstained with DAPI. Images were examined at 100x magnification under a Zeiss
Axiphot fluorescence microscope equipped with FITC, DAPI and triple band pass filter sets.
Digital images were captured by computer using Applied Imaging Probevision software
(Pittsburgh), and photographs were printed on a Kodak XL 7700 color image printer.

RNA Isolation
Total RNA was extracted from lymphoblastoid cell lines using the GenElute™
Mammalian Total RNA Purification Kit (Sigma) according to the manufacturer’s protocols.
Samples were treated with TURBO™ DNase (Ambion, Inc.) using 2 units / 50 Rg RNA at
37°C for 30 minutes. RNA was subsequently purified using the RNeasy Mini Kit (Qiagen)
following the manufacturer’s protocols.

Quantitative Real-Time PCR
Quantitative Real-Time PCR was performed using the iScript™ One-Step RT-PCR
Kit with SYBR® Green (BioRad) on an iCycler iQ™ Real-Time PCR detection System
(BioRad). The experimental primer pairs sequences were: ABCD3ex5-6 Forward – 5’agtggtatcattggtcgtagcag -3’, Reverse – 5’-gagccttactcggaagcacag -3’(140 bp product);
ZNF184ex3-4 Forward – 5’-ccaagggggacataatctactctc -3’, Reverse – 5’-atggctctgtcccttgctctaa
-3’(224 bp product). For the reference gene, a primer pair amplifying a portion of the
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coding region of the RPII gene was used. The primer sequences were: Forward – 5’gcaccacgtccaatgacat -3’, Reverse – 5-gtgcggctgcttccataa -3’ (267 bp product). The cycling
conditions used an initial 10 minute first strand synthesis step at 50°C followed by a 5
minute denaturation step at 95°C. Two-step amplification was performed by cycling
between 95°C for 10 seconds and annealing/extension at 56°C (ABCD3), 57°C (ZNF184),
or 60°C (RPII) for 30 seconds 45 times. Data was analyzed using the iCycler iQ™ software
to generate a standard curve for each gene and calculate the fluorescence generated from the
experimental primer pairs relative to RPII using the comparative Ct method.

Northern Analysis
Northern analysis was performed as described previously (Sambrook and Russell,
2001). Twenty Rg total RNA was resolved on a 1.5% denaturing agarose gel and transferred
to Hybond+ (GE Healthcare) filter overnight using the downward capillary transfer method
(Chomczynski, 1992). The filter was hybridized with a cDNA probe spanning exons 1-3 of
ABCD3 (208 bp). The probes were labeled with [32P]-dCTP using the RadPrime DNA
Labeling System (Invitrogen) and hybridization was performed following the ExpressHyb
(BD Biosciences) protocol. The filter was washed at high stringency according to the
manufacturer’s recommendations. The filter was exposed to X-ray Biomax film (Kodak) at
-80°C for 4 days.
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Results
Delineation of translocation breakpoint critical regions
The patients karyotype was previously determined to be t(1:6)(p22.1;p22.2)
(Asamoah et al., 2003). Physically mapped genomic clones from the Genomic contigs
NT_032977.8 (chromosome 1) and NT_007592.14 (Chromosome 6) were identified and
used systematically in FISH analysis to map the translocation breakpoint critical regions.
(Figure 2.1 a,b ).
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Figure 2.1 Delineation of translocation breakpoint critical regions and candidate genes.
Physically mapped BAC clones used in FISH analysis on chromosome 1 (a) and
chromosome 6 (b) are indicated. Clones distal to the breakpoint are shown in orange.
Clones spanning the breakpoint are shown in purple. Clones distal to the breakpoint are
shown in green. Candidate genes from the region flanking the breakpoint critical regions are
noted with arrows showing direction of transcription. Translocation critical region is shown
by double purple lines.
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The boundaries of the chromosome 1 breakpoint region were initially established
with the probe RP11-148B18, which was distal to the breakpoint giving signals on the
normal chromosome 1 and the derivative chromosome 6, and probe RP11-122C9, which
was proximal to the breakpoint giving signals on both the normal and derivative
chromosome 1 (Fig. 2.1a). Subsequent analysis found the probes RP11-86H7, RP11-465K1,
RP11-57H12, and RP11-146P11 all to be proximal to the translocation breakpoint giving
signals on both the normal and derivative chromosome 1 (Fig. 2.1a). Probe RP11-366L18
spans the distance between RP11-148B18 and RP11-86H7. RP11-366L18 showed a split
signal between the derivative chromosome 1 and the derivative chromosome 6, in addition
to the normal chromosome 1, suggesting it spans the translocation breakpoint (Fig. 2.1a,
2.2b). To narrow the chromosome 1p22.1 breakpoint region within the 96 kb clone RP11366L18, a second clone, RP11-6J23, which spanned a large portion of both clones RP11148B18 and RP11-366L18 was used. RP11-6J23 was also found to show a split signal
between the derivative chromosome 1 and the derivative chromosome 6, in addition to the
normal chromosome 1 (Fig. 2.1a, 2.2a). This result showed that RP11-6J23 also spans the
translocation breakpoint and narrows the translocation breakpoint critical region to the distal
end of RP11-366L18 (Fig. 2.1a).
The distal boundary to the chromosome 6 translocation critical region was initially
narrowed by the probes RP3-425P112 and RP1-45P21, both of which mapped distal to the
breakpoint showing signals on the normal chromosome 6 and derivative chromosome 1
(Fig. 2.1b). Subsequent analysis with clone RP1-153G14 also resulted in a distal signal
present on the normal chromosome 6 and derivative chromosome 1 (Fig. 2.1b). The
proximal boundary was identified through the probes RP1-29K1, RP11-150A6, and RP1-
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97D16, all of which mapped proximal to the breakpoint with signals on both the normal and
derivative chromosome 6 (Fig. 2.1b). Probe RP11-999A17 lies between the distal boundary
identified through RP1-153G14 and the proximal boundary identified by RP1-97D16.
RP11-999A17 was also found to be proximal to the breakpoint (Fig. 2.1b). RP11-106D17
partially overlaps both RP1-97D16 and RP11-999A17. RP11-106D17 was found to span the
translocation breakpoint with signal present on the derivative chromosome 6, the derivative
chromosome 1, and the normal chromosome 6 (Fig. 2.1b, 2.2c).
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Figure 2.2 FISH analysis of Chromosome 1 and 6. (a) FISH analysis of the spanning
probe RP11-6J23 (green). Chromosome 1 centromeric control probes are shown in red. (b)
FISH analysis of the spanning probe RP11-366L18 (green). Chromosome 1 centromeric
control probes are shown in red. (c) FISH analysis of the spanning probe RP11-106D17
(green). Chromosome 6 centromeric control probes are shown in red.

Identification of ED Candidate Genes
Sequence information corresponding to the translocation critical regions was
obtained from the NCBI database. End sequences of BAC/PAC clones from the critical
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region were analyzed further and the physical map of the overlapping genomic clones was
determined. On chromosome 1, four probes in particular were informative in identifying
the translocation critical regions. The ends of clones RP11-148B18 (distal), RP11-366L18
(spans breakpoint), and RP11-86H7 (proximal) overlap (Fig 2.1a). The clone RP11-6J23 is
almost bisected by the overlap between RP11-148B18 and RP11-366L18 (Fig. 2.1a). The
fact that clones RP11-6J23 and RP11-366L18 both show a signals in FISH analysis which
span the breakpoint means that the translocation must lie within the approximately 60 kb of
overlap between RP11-6J23 and RP11-366L18 (Fig.2.1a).
Since no overlap between the clone ends exists between RP11-106D17 and the
proximal and distal clones RP11-999A17 and RP1-153G14, the critical region cannot be
narrowed significantly beyond the 170 kb size of the RP11-106D17 using FISH analysis.
Since resolution in FISH is somewhat limited and probe intensity was strong, albeit not
equal, on each of the derivative chromosomes, it is safe to assume the translocation
breakpoint does not lie in the 15 kb ends of this clone. Based on this evidence, the
translocation breakpoint critical region on chromosome 6 has been narrowed to
approximately 140 kb within the clone RP11-106D17 (Fig. 2.1b).
In silico analysis of the gene content of the 1p22.1 and 6p22.2 regions and the
flanking regions showed the presence of known and putative genes (Fig. 2.1a,b).
Chromosome 1 was found to have five known genes and one predicted gene with in 500 kb
of translocation breakpoint critical region (Fig 2.1a). Two genes, F3 and SLC44A3, are
located on the centromeric side of the critical region (Fig. 2.1a). F3 (GenBank accession no.
BC011029) codes for coagulation factor III, a cell surface glycoprotein. F3 is known to be
an integral member of the clotting pathway and is considered a poor candidate gene.
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SLC44A3 (GenBank accession no. BC033858) is largely uncharacterized. Sequence analysis
predicts it to be an integral membrane protein. The telomeric side of the translocation
breakpoint on chromosome 1 also has two known genes, ABCA4 and ARHGAP29.
ABCA4 (GenBank accession no. U88667) is an interesting candidate gene that is associated
with retinal abnormalities (Maugeri et al., 2000). Recent reports have shown that restoration
of the Ta allele in Tabby mice improves eye health (Cui et al., 2005). But this is probably due
to restoration of proper tear gland function and not linked to retina development.
ARHGAP29 (GenBank RefSeq no. NM_004815) is also an interesting candidate gene. It
has been shown to in interact with Rho and cause mutant Rho-like changes in fibroblast
cytoskeleton when ARHGAP29 is suppressed. Rho proteins have recently been implicated
in MR, suggesting this gene could be the cause of the neurological findings in this patient if
it is indeed affected by the translocation (Benarroch, 2007). The 5’ portion of ABCD3
overlaps with the telomeric side of the chromosome 1 critical region. ABCD3 (GenBank
accession no. M81182) is a membrane protein that is thought to be involved in peroxisome
biogenesis; however its exact function is still in question (OMIM 170995). It was originally
linked to the biochemical disorder Zellweger syndrome, but this association has
subsequently been questioned (Paton et al., 1997).
The chromosome 6 critical region is in a relatively gene poor region. There are
two known Zinc finger genes, ZNF184 (GenBank accession no. U66561 ) and ZNF204
(GenBank accession no. AF033199), near the critical regions, as well as the hypothetical gene
LOC645950. The Zinc finger genes belong to a large family of proteins, some of which are
transcription factors, that can bind DNA, RNA, and even proteins (Gamsjaeger et al., 2007).
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LOC645950 is a hypothetical gene. Attempts to amplify this gene through primers designed
from the EST databases were unsuccessful.

Candidate ED Gene Expression Analysis
Candidate gene expression was measured by real-time RT-PCR. Four candidate
genes could not be checked by this method because of absent (ABCA4, ARHGAP34, and
ZNF204) or limited (SLC44A3) expression in lymphoblastoid cell lines (UniGene Hs.8198,
UniGene Hs.416707, UniGene Hs.483238, and UniGene Hs.483423). The two genes that
could be check through real-time RT-PCR were ZNF184, the closest candidate gene to the
chromosome 6 critical region, and ABCD3, which partially overlaps with the chromosome 1
critical region. Real-time RT-PCR results for these genes are shown in Figure 2.3. Neither
gene appears to have an altered transcript level in the patient as compared to controls.

ABCD3 Northern Analysis
Because the 5’ portion of ABCD3 is located in the chromosome 1 translocation
breakpoint critical region, a chimeric transcript could be produced and result in the
phenotype. If a chimeric transcript is formed, it would likely be of a different size than the
normal ABCD3 mRNA. To test for the presence of a chimeric transcript, we performed
Northern analysis on the patients RNA using a probe spanning exon 1-3 on ABCD3. The
northern blot showed only the expected 4 kb band size of a normal ABCD3 transcript (Fig.
2.4).
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Figure 2.3 Normalized relative expression for ABCD3 and ZNF184. No significant
difference in expression was seen between the patient, CMS8770, and four control
individuals (CMS4633, CMS6265, CMS5865, and CMS5863) for either gene tested. Realtime RT-PCR was performed in triplicate.
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Figure 2.4 ABCD3 Northern analysis in patient CMS8870. (a) Northern analysis using a
cDNA probe spanning exons 1-3 of ABCD3 yielded an approximately 4 kb band in the
patient (CMS8770) and normal controls (CMS6265, CMS4633, CMS5865) indicated by the
double headed black arrow. No evidence of a chimeric transcript of a differing size from the
normal transcript was present. (b) Ethidium bromide stained gel picture shows the lane
abnormality visible directly above the ABCD3 band is the 28S ribosomal RNA band.

Discussion
This study has identified the translocation breakpoint critical regions in a patient with
ED, mild MR, and a karyotype of 46,XX,t(1;6)(p22.1;p22.2) . The closest gene to the
chromosome 1 breakpoint critical region is ABCD3. Real-time RT-PCR did not indicate
changes in expression of this gene in lymphoblastoid cells from the patient and Northern
analysis failed to show the presence of a chimeric transcript resulting from the translocation.
Taken together, these results suggest ABCD3 is not physically disrupted by the translocation.
There is no known gene present in the chromosome 6 translocation critical region.
This suggest that any deleterious affect of the translocation would likely be the result of a
disruption in a distant transcriptional control sites for genes flanking the translocation
breakpoint critical region. There are several examples in the literature of the long range
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effects translocations can have on flanking gene expression (Crisponi et al., 2001). In such
cases, the translocation often separates the target gene from a cis regulatory element. As a
result, expression of the target gene can be either up-regulated or down-regulated.
On chromosome 1, we have narrowed the breakpoint critical region to a maximum
of 60 kb. This implicates as candidate genes ABCA4, ARHGAP29, ABCD3, and
SLC44A3. The critical region on chromosome 6 has been narrowed to 140 kb. Two zinc
finger genes, ZNF204 and ZNF184, are located near this critical region. There is no known
ED gene located in either breakpoint critical region.
Initial screening of the candidate genes in this region has been hampered because
several are either not expressed in blood or expressed at extremely low levels. No other cell
line from this patient is currently available for study. The two candidate genes that could be
screened using mRNA derived from lymphoblastoid cell lines, ZNF184 and ABCD3,
showed no change in expression compared to controls. Northern analysis using probes for
the 5’ portion of ABCD3 did not detect any altered transcripts. These genes remain good
candidate genes for the phenotype.
ABCD3 and ABCA4 are both members of the ABC gene family. The ABC gene
family codes for a large group of transmembrane proteins involved in the active transport of
target molecules across cell membranes or , in a small subgroup, the regulation of ion
channels (Gottesman and Ambudkar, 2001). The ABC family of transporters have been
linked to such human diseases as retinopathies, cystic fibrosis, and cardiomyopathies
(Schuierer and Langmann, 2005). Recently, ABCA2 and ABCA3 were shown to play an
important role in neural stem cell proliferation, differentiation, and regulation (Lin et al.,
2006). Changes in expression patterns of ABC transporters have been linked to a significant
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number of drug resistant cancers (Schuierer and Langmann, 2005). Given the large number
of cellular processes affected by this group, it would be completely plausible that either
candidate gene identified here could be the cause of the MR or ED seen in the patient.
ABCD3 is a peroxisomal membrane protein involved in the biogenesis of
peroxisomes and the transfer of long chain acyl-CoA across peroxisomal membranes
(Imanaka et al., 1999). ABCD3 was once linked to the biochemical disorder Zellweger
syndrome, but this association has subsequently been questioned (Paton et al., 1997). It also
has been shown that SOD1 mutant mice, a model for amyotrophic lateral sclerosis, have
decreased ABCD3 levels, which might be the cause of the decrease in peroxisomal function
and increase in oxidative stress resulting in neuronal loss. (Ilieva et al., 2003). It remains to
be seen as to whether ABCD3 plays a role in either phenotype in our patient.
Mutations in ABCA4 have a wide phenotypic spectrum (Valverde et al., 2007).
ABCA4 mutations are linked to Stargardt disease, the most common juvenile macular
dystrophy, autosomal recessive cone-rod dystrophy, and retinitis pigmentosa (RiveiroAlvarez et al., 2007; Valverde et al., 2007). The eye is derived from the ectodermal germ
layer, so there could be a link between a gene involved in retinal development and that of
other ectodermally derived structures. However, of the large number of patients tested in
recent ABCA4 mutation studies, none were reported to have either epidermal defects or MR
(Riveiro-Alvarez et al., 2007; Valverde et al., 2007).
Of all of the candidate genes identified in this study, ARHGAP29 is possibly the
best candidate gene for the MR seen in the patient. ARHGAP29 is a GTPase which has
been shown to regulate Rho activity (Saras et al., 1997). Rho proteins act as directors of
cytoskeleton organization in dendrites, dentritic spines, and axons controling the growth and
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development of these structures (Benarroch, 2007). With a role integral as this to the proper
connection and maintenance of synapses, it is understandable why Rho proteins and their
effectors are being implicated in MR. If ARHGAP29 is linked to the ED phenotype seen in
the patient, it would be the first such association between Rho signaling and ectodermal
development.
Little is known about the other three candidate genes, ZNF184, ZNF204, and
SLC44A3. A role in MR or HED could be imagined for ZNF184 or ZNF204 if either are
found to have altered expression, given the Zinc finger family’s frequent role as transcription
factors. Initial studies on ZNF184 expression show no difference in the patient and control,
suggesting it is not affected by the translocation. SLC44A3 is a membrane protein that is
predicted to act as a solute carrier and expressed at low levels in both skin and brain
(UniGene Hs.483423).
There is a question of whether one gene is responsible for both the MR and HED
phenotype seen in the patient or if two different genes are affected by the translocation. If,
in fact, there is one gene resulting in both phenotypes, this would be the first instance of an
HED gene mutation affecting neural function. It is more likely that two separate genes have
been affected by the translocation. To answer this question completely, expression data
must be obtained for the remaining candidate genes bordering the translocation breakpoint
critical regions.
There remains the possibility that the MR seen in the patient is not the result of the
translocation and is, in fact, the result of a separate cause. This hypothesis is supported by
the patient’s family history. For this to be the case, the MR causing mutation would have to
exhibit incomplete penetrance as the patient’s father is apparently normal. Alternately, the
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patients MR could be the result of a compound heterozygous mutation with one allele
coming from her mother and another coming from her father. This being stated, it is more
likely that the patient’s MR is the result of a gene or genes affected by the translocation.
Other causes cannot be ruled out at this juncture.
Future studies will help identify the cause of the phenotype seen in this patient.
Further narrowing of the breakpoints may give insights into why the translocation occurred.
Addition patient samples, particularly from a different tissue type such as a skin punch
yielding fibroblasts, will help finish the screening of the candidate genes in the region.
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DEDICATOR OF CYTOKINESIS 8 (DOCK8) IS DISRUPTED IN A PATIENT WITH
ECTODERMAL DYSPLASIA, MENTAL RETARDATION, AND A
SUBTELOMERIC 9p REARRANGEMENT
Introduction
Ectodermal dysplasia (ED) is a developmental disorder in which secondarily derived
ectodermal structures such as hair, teeth, and sweat glands do not form correctly.
Ectodysplasin-1 (EDA), has been shown to be the gene responsible for the X-linked
hypohydrotic ectodermal dysplasia (HED), the most common form of ED (Ezer et al., 1999;
Mikkola et al., 1999).
There was long a proposed association in the literature of cognitive involvement in
the ED phenotype in the form of mental retardation (MR). Tanner criticized these
exaggerated claims made by some authors that upwards of 50% of ED patients had
cognitive involvement (Tanner, 1985). Although some patients, even those used in the
initial mapping of the EDA gene such as AnLy, do have MR, this is known to be a rare
occurrence. Larger studies have shown that MR is in fact rarely seen in HED patients
(Clarke, 1987). The current understanding of the EDA signaling pathway (see Figure P.2)
supports this. There are no known EDA signaling pathway proteins whose mutation also
results in MR (Cui and Schlessinger, 2006). It is now generally accepted that MR seen in ED
patients such as AnLy is the result of genes either disrupted by translocation breakpoints or
due to a defect in a MR gene located elsewhere in the genome.
MR is the most common developmental disability, affecting intellectual and adaptive
functions in approximately 1-3% of the population. Yet, the underlying cause of MR is
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established in less than half the cases (Stevenson, 2005; Ropers, 2006). Genetic factors in
MR likely include mutations in genes distributed throughout the genome and are already well
established for the genes on the X chromosome (Stevenson, 2005; Ropers, 2006). The
finding of MR among almost all patients with autosomal microdeletions and the association
of MR with submicroscopic alterations in the subtelomeric region of the autosomes further
indicates the ubiquitous distribution of autosomal genes that influence intelligence (Brewer
et al., 1998; Colleaux et al., 2001; Anderlid et al., 2002).
Chromosomal abnormalities have been found in a significant number (4-34%) of
individuals with MR and developmental disabilities (reviewed by Xu and Chen 2003). About
5% of idiopathic MR can be explained by deletions or rearrangements of the subtelomeric
regions of the autosomes (Knight et al., 1999; de Vries et al., 2000; Rossi et al., 2001;
Anderlid et al., 2002; De Vries et al., 2003; Xu and Chen, 2003). A large number of
subtelomeric deletions have been observed in patients with MR and suggests that these
deletions are likely to harbor gene(s) responsible for the observed phenotypes in these
patients. Furthermore, analysis of patients with submicroscopic deletions has facilitated
identification of small regions of overlap linked to specific phenotypic characteristics and
subsequent isolation of the causative genes. Recently, disruption of the Eu-HMTase1 gene
has been shown to be associated with the 9q34 subtelomeric deletion syndrome (Kleefstra et
al., 2005; Kleefstra et al., 2006).
In this study, the 9p24 chromosomal breakpoints in one patient with HED and MR
were characterized at the DNA level. Additionally, a new patient who also has a 9p
rearrangement including the region affected in patient 1 was also studied. The DOCK8 gene,
which lies with in the 9p24 critical region, was characterized. DOCK8 was shown to be
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expressed in fetal and adult human brains and the longest isoform of the gene is physically
disrupted in both patients.

Material and methods
Case report
Case 1 (CMS1485, alias “ANLY”) has been previously described (MacDermot and
Hulten, 1990; Thomas et al., 1993; Kere et al., 1996; Srivastava et al., 1996). This female
patient was diagnosed with ectodermal dysplasia (HED), mental retardation, and had a de
novo balanced translocation t(X;9)(q13.1;p24). The patient was reported to have delayed
speech and psychomotor development. At age 7, she reportedly had education in a special
school and a psychological assessment showed her functioning at the lower end of the
moderate MR range (MacDermot and Hulten, 1990).
Case 2 (CMS6482) is a 47 year old white male with profound mental retardation (IQ
2). He was born at term to a 19 year old mother who had an appendectomy at 4 months
gestation. He was reported to weigh 14 pounds. He walked at age 11 months. At one year
of age, he was found to have a seizure disorder, unusual posturing and no speech. As an
adult, he developed cataract with presbyopia and a cholesteatoma of the right ear. Physical
examination at age 47 revealed his height to be 166.5 cm, weight 61 kg and head
circumference 55 cm. He had no speech. He had significant balding, prominent supraorbital
ridges, recessed eyes, midface hypoplasia, and a square chin. His ears measured 7.7 cm
bilaterally with the left having a more simple architecture. His finger tips were somewhat
squared at the tip with prominent pads. The distal phalanx of the left third finger was
missing from an accidental amputation. He walked with a stooped over posture. Normal

61

laboratory studies included routine chromosome analysis, FMR1 gene analysis, urine
creatine, urine organic acids, and plasma amino acids. Subtelomeric FISH analysis revealed
the 9p deletion (ish 9ptel(30557x1)).

Cell culture
Fibroblast cell lines corresponding to patient CMS1485 (GM00705A) and a control
sample CMS11195 (GM03652F) were obtained from NIGMS human genetic mutant cell
repository, Coriell Institute for Medical Research (Camden, NJ). Peripheral blood
lymphocytes of case 2 (CMS6482) were immortalized by Epstein-Barr virus transformation
to establish a lymphoblastoid cell line. These cell lines were used for FISH experiments,
RNA preparations, and genomic DNA preparations.

Molecular cytogenetics
Genomic contigs, clones, markers, mapping and sequence information were obtained
from the NCBI (http://www.ncbi.nlm.nih.gov/genome/guide/human) databases. BAC and
PAC probe preparation, hybridization, staining, and visualization has previously been
descried in the methods section of the previous chapter (pg. 39). The metaphase
chromosome spreads were obtained from lymphoblastoid cells (CMS6482) or from
fibroblast cell (CMS1485) using conventional methods.

Pulsed-field gel electrophoresis (PFGE)
High molecular weight DNA was isolated from patient fibroblasts in agarose plugs
(Sambrook and Russell, 2001). The plugs were digested with 80U of Sal1 for 16 hours in
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appropriate endonuclease buffer. Digested fragments were separated by electrophoresis on a
1% Seakem® Gold agarose gel (Cambrex) at 6 V/cm for 22 hours, at 12ºC in 0.5X TBE
running buffer, using a 45 sec pulse time on a CHEF-DR® III apparatus (Bio-Rad). After
electrophoresis, samples were transferred to a Hybond-N+ membrane (GE Healthcare)
using an alkaline downward transfer procedure (Chomczynski, 1992). The filters were prehybridized at 65°C for 2-3 hours in aqueous hybridization solution before adding the
denatured probe.
A 938 bp cDNA amplicon spanning from DOCK8 exon 41 to a portion of 47 was
amplified using primers D8ex41.47 Forward – 5’- TCACATAGACTAGAGGCATTTTA 3’, Reverse – 5’- GATCAGGGAGTGTACAGTCAGTC -3’. The cDNA hybridization
probe was labeled with [32P]-dCTP using the RadPrime DNA Labeling System (Invitrogen).

Quantitative Real-Time PCR
Genomic Quantitative PCR was performed using iQ™ SYBR® Green Supermix (BioRad) on an iCycler iQ™ Real-Time PCR detection System (Bio-Rad). The experimental
primer pairs sequences were: IVS13/F26IVS7 Forward – 5’TTTTTGTCTTTGCCCCTCTGTA -3’, Reverse – 5’-TGTCTGGCCACCTCGCTGTAA 3’(333 bp product); Exon18/D8ex18 Forward – 5’-TTGCTTGTTAGTAATCAGAAAAG 3’, Reverse – 5’-GTCCCCACAAAGAACTAAAG -3’(294 bp product); IVS23/D8IVS23a
Forward – 5’-TCTCGCAGTGACATCCTC -3’, Reverse – 5’ATTTGTGCTTTCTTCTCAGTG -3’(151 bp product); Exon29/D8ex29 Forward – 5’TGGGGAAATGTCATGTTTGA -3’, Reverse – 5’-CAGACACATGTGCACCAACA 3’(214 bp product); Exon34/D8ex34 Forward – 5’-CTGAGCTAATTGTCAGGAAC -3’,
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Reverse – 5’-GAAGCTAGATGAGAATCTTACTC -3’(272 bp product). For the reference
gene, a primer pair amplifying exon 16 of the NEPH2 gene was used. The primer sequences
were: Forward – 5’-GGGCCATCAGAGCTAAAGACC -3’, Reverse – 5CTTGGGGGAAGTGGAGGTTTA -3’ (210 bp product). The cycling conditions used an
initial 5 minute denaturation step at 95°C followed by the two-step amplification cycles at
95°C for 10 seconds and 58°C for 30 seconds repeated 40 times. Data was analyzed using
the iCycler iQ™ software to generate a standard curve for each gene and calculate the
fluorescence generated from the experimental primer pairs relative to NEPH2 using the
comparative Ct method.

Expression Studies
Northern blots (Multiple Tissue Blots, BD Biosciences and Origene) containing poly
A+ RNAs from different human adult and fetal tissues and poly A+ RNAs from different
human brain sections (from individuals of ages 16-75 years) were hybridized with a 867 bp
DOCK8 cDNA probe spanning exons 2-9 or with a 457 bp DOCK8 cDNA probe spanning
exons 22-25. The probes were labeled with [32P]-dCTP using the RadPrime DNA Labeling
System (Invitrogen) and hybridization was performed following the ExpressHyb (BD
Biosciences) protocol. Filters were washed at high stringency according to the
manufacturer’s recommendations.
Expression of DOCK8 in fetal tissues was also measured by RT-PCR using a human
fetal multiple tissue cDNA panel (BD Bioscience) and the D8ex41.47 primer pair. Isoform
specific primers were used to examine expression of the DOCK8 gene splice variants.
Variant 1, Dock8ex13-14 Forward 5’- AACGGCTCCTGTGTGTTCTT -3’, Reverse 5’-
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TTGTAATGTTCCGGGCTGAT -3’ (155 bp product; annealing temperature 60oC);
Variant 2, Dock8ex13a-14 Forward 5’- GGGAAGACCATCTGCACCT -3’, Reverse 5’TCAGCCTCTGTGGGTAGACA -3’ (396 bp product; annealing temperature 60oC);
Variant 3, Dock8ex15-17 Forward 5’- CAGCGGGCCTGAATTTCT -3’, Reverse 5’TGGGAGACAGTAGGATCCAGTT -3’ (247 bp product; annealing temperature 60oC).

Mutation Screening
A patient cohort consisting of 180 females with MR was screened for mutations in
DOCK8. These patients were previously tested negative for the MR-causing FMR1
expansion. Amplicons corresponding to each exon (Table 3.1) were analyzed using
Incorporation PCR SSCP (IPS) or Denaturing High Performance Liquid Chromatography
(dHPLC) as previously described (Huber et al., 1993; Sossey-Alaoui et al., 1999). Primer pair
details are listed in Table 3.1.
Both strands of PCR products from patients with abnormally migrating fragments
and a normal control were amplified and sequenced using DYEnamic ET Dye Terminator
Cycle sequencing Kit (GE Healthcare) and an automated MegaBACE 1000 DNA Analysis
system (GE Healthcare). Sequences were analyzed using the DNASTAR Lasergene
program (DNASTAR).
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Table 3.1 Mutation screen primers
Name

Forward Primer (5’-3’)

DOCK8 ex1

cagcacagcagcactcttgc

cattaatgacgcaacacac

253

Annealing
Temperature (°C)
61

DOCK8 ex2

catctactattgcctttgtgc

tcatgacaatcccaatcac

295

61

Reverse Primer (5’-3’)

Length (bp)

DOCK8 ex3

attcgtgtcatgttccttgc

gtgtgtgatatggagtgg

322

54

DOCK8 ex4

accatgtctacacttaag

ctttctatgcgtctatcg

326

56

DOCK8 ex5

gacatccaagattcttcgg

tacaagtgagccctgacacc

403

60

DOCK8 ex6

ggttgggggttggaagagaa

taaagcggtggcagtgtg

289

60

DOCK8 ex7

gtttatctatctaggtgttttcag

ttatgtgccttagggatggat

188

61

DOCK8 ex8

aacaggtctaacttatatttcac

atgggcaaatcagatcg

220

58

DOCK8 ex9

ttatggatgtaatttatgtgcc

gcacattagggactaaagc

231

56

DOCK8 ex10

gtcagaggcagttgacttgg

ccgctagtaagctgtggac

299

60

DOCK8 ex11

catattcagtgttcctgatcag

accagacacactgtaatgtg

279

60

DOCK8 ex12

cgtttgtccccaacccaagag

gtaagcagttttggcacagc

207

61

DOCK8 ex13

gattccctcataacatgacag

ccccagcccgagcctgtg

273

60

DOCK8 ex14

caccccatgaatggaagtct

cctgatttgaggcaaatgt

248

60

DOCK8 ex15

gaacatcctgttggcctgat

tgaaaaaccaggagatgatg

217

60

DOCK8 ex16

gctgtggcgttttacaatca

atcagcaggctggaaacaa

239

60

DOCK8 ex17

tgcatttgattattgcgagcta

ggaaggtggtccaagacta

249

60

DOCK8 ex18

ttgcttgttagtaatcagaaaag

gccccacaaagaactaaag

294

60

DOCK8 ex19

atgaggcctgccttctcc

cagccctgcaggttcatac

281

60

DOCK8 ex20

cagctgtgggactacccatt

cacactcagggcaactcta

224

60

DOCK8 ex21

tgacatgtctctgcctggtg

cttccacggtttgacatct

228

60

DOCK8 ex22

cctttccatggttggttgac

ggtgagggcatgaggaaat

211

60

DOCK8 ex23

catgcttcaggaacgaacaa

cgatacaaacgcgcaagaa

238

60

DOCK8 ex24

agcaggtcaccaatctccat

tttccaggtaaacaatttagaaaa

245

58

DOCK8 ex25

caaatccagagtgtcccaca

catggcaacgaacatcacat

240

60

DOCK8 ex26

tgccaacctcaactccactt

tggaaatacatgattaaactgagcta

300

60

DOCK8 ex27

ctggccatcgctattttcat

tttggcttcatcttccatttt

243

60

DOCK8 ex28

tcctttcaccataacctcttga

cccaacaatccaagaaaga

250

58

DOCK8 ex29

tggggaaatgtcatgtttga

ccacacatgtgcaccaaca

214

60

DOCK8 ex30

acttcttccctggcctccat

aagttgtgccactccagactt

248

60

DOCK8 ex31

acggagatctcaccaaagga

acattcctccccacaaacag

244

60

DOCK8 ex32

ggtgctgaggcttctcagtt

tagcagaaagttgccgagtg

212

60

DOCK8 ex33

caggtttgacatgcgcttta

ttcatggccaacaaatcaga

182

60

DOCK8 ex34

ctgagctaattgtcaggaac

gaagctagatgagaatcttactc

272

60

DOCK8 ex35

ctgccaagtgatgcctaatg

ccaggtcactcagctggttt

223

60

DOCK8 ex36

gctttcagttatctactgctaagtgtg

caaggtatgtgcttcggtgt

249

61

DOCK8 ex37

agtctctgctgccctctgat

tgtcccttgagtgtgtcagg

250

60

DOCK8 ex38

tgtcctcaaaactacttctcactca

aaaagctgcacacaccctac

250

60

DOCK8 ex39

ctagtctggtcgccctgttc

atgccctctgggcactgac

211

62

DOCK8 ex40

gacaatgacctctggttgctc

gccaccaggtaacaagacct

250

61

DOCK8 ex41

tggctcctcaggatgacata

aggcgcacagaatcactttt

213

60

DOCK8 ex42

gaactctcaataatcagtgaac

ggtagagaacgaagggatttag

274

60
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Table 3.1 Continued
Name

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

Length (bp)

Annealing
Temperature (°C)

DOCK8 ex43

ccattgcgtcagggatggcc

gggtttgtgggtcctcctg

377

60

DOCK8 ex44
DOCK8 ex45

ctgtcatagctccaggcttgtc
agggaccactggaagtagcc

catggatcaaagtcctcatc
cactgctctactgaaattc

324
149

60
60

DOCK8 ex46

tctaagcacttcaaagtc

cgctaggccccatgcgctg

286

60

DOCK8 ex47

acgctctctttccctctcct

cagtccttctccagggttg

159

60

DOCK8 ex45

agggaccactggaagtagcc

cactgctctactgaaattc

149

60

Fluorescence microscopy
The fibroblast cell lines CMS1485 and CMS11195 were seeded onto Nunc Lab-Tek
II CC2 chambered slides (Nalge Nunc International, Naperville, IL) at a density of 15,000
cells per well. Cells were grown overnight and then stained with Alexa Fluor® 488 phalloidin
green and SYTOX® orange (Invitrogen). Briefly, cells were washed two times with PBS and
fixed with 4% para-formaldehyde for 5 minutes. Cells were then permeabilized with 0.1%
Triton X-100 in PBS for 5 minutes followed by washing twice with PBS. The cells were
then incubated with a quenching solution (1.02 g sodium acetate in 50 ml PBS) twice for 8
minutes each. Cells were then incubated for 30 minutes in a blocking solution (2% horse
sera, 0.4% BSA in PBS) with 200 Rg/ml RNaseA. Alexa Fluor® 488 phalloidin green
diluted 1:200 in the blocking solution was applied to the cells for 1 hour at room
temperature. Cells were rinsed in triplicate for 5 minute durations in blocking solution
followed by a final rinse in TS (10mM Tris-HCl pH 7.5, 15 mM NaCl). SYTOX® orange
was diluted to 2 RM in TS and added to cells for 7 minutes at room temperature. The cells
were rinsed 4 times with PBS. Imaging was performed on an Axiovert 200 Laser Scanning
Microscope (Zeiss).
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Results
Re-analysis of the de novo t(X;9)(q13;p24) translocation in a female patient with HED and MR
The Xq13 chromosome breakpoint in patient CMS1485 was previously mapped
within intron 1 of the EDA gene (Xq13) and it was determined that the ectodermal defects
in this female patient (CMS1485) were due to the disruption of the EDA gene (Kere et al.,
1996; Srivastava et al., 1996). Thus, the MR is presumably associated with the 9p24
breakpoint in this patient. To refine the 9p24 chromosomal breakpoint, FISH analysis was
performed, using three clones spaced across chromosomal band 9p24. All three clones
initially used (RP11-130C19, RP11-125K10, and RP11-376O21) mapped proximal to the 9p
breakpoint and gave signals on both the normal chromosome 9 and the derivative
chromosome 9 (Table 3.2). FISH analysis with additional clones narrowed the location of
the 9p breakpoint to a position between the clones RP11-174M15 and RP11-165F24 (Fig
3.1). Clones RP11-143M1 and RP11-174M15 mapped distal to the breakpoint (Table 3.2).
Both probes gave FISH signals on the normal chromosome 9, but also gave a 9p-specific
signal on the derivative X chromosome. Clone RP11-165F24 mapped proximal to the
breakpoint and gave signals on both the normal and derivative chromosome 9 (Fig. 3.2a,
Table 3.2). Clone RP11-59O6 was found to map distal to the breakpoint (Table 3.2).
Genomic clone RP11-910H2 partially overlaps both RP11-59O6 and RP11-165F24 (Fig.
3.1). FISH analysis with RP11-910H2 revealed signals on the normal chromosome 9 and the
derivative X chromosome (Fig. 3.2a, Table 3.2). These results suggest the chromosome 9
translocation breakpoint lies within the overlap of these two adjacent and partially
overlapping clones (RP11-59O6 and RP11-165F24), further narrowing the translocation
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breakpoint region (Fig. 3.1) and also suggested the possibility of a microdeletion at the
breakpoint.

Chromosome 9
24

21

13

12

21

22

32

pter

34

qter

NT_008413
pter
0.1 mb

305J7
Clones

RP11-143M1

0.4 mb

0.3 mb

0.2 mb

RP11-910H2
RP11-59O6

RP11-174M15

Genes

FOXD4

0.5 mb

CBWD1

RP11-165F24

C9orf66

DOCK8

Deleted region in CMS6482
Translocation
breakpoint critical
region

Figure 3.1 Mapping of the subtelomeric 9p chromosomal rearrangements. Ideogram of chromosome 9 with a
partial physical map of the subtelomeric 9p24.3 region, BAC clones used in FISH analysis, and known genes in
italics are shown. Black arrows indicate the direction of the transcription. FISH analyses determined a critical
deletion region (red bar) in patient CMS6482 and a region (blue bar) harboring the 9p24 translocation
breakpoint in CMS1495.

Molecular analysis of the subtelomeric deletion in a patient with MR/DD
Subtelomeric FISH analysis revealed deletion of a probe from the 9p subtelomeric
region (ish 9pter (305J7-T7 x1) in patient CMS6482 (Fig. 3.1 and 3.2b). This probe was
found to map within a genomic contig (NT_008413; NCBI) in 9p24.3 (Fig. 3.1). We
identified physically mapped genomic clones from the contig and used them systematically in
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FISH analyses to determine the extent of the subtelomeric 9p deletions in this patient (Fig.
3.1 and Table 3.2). A part of the 9p subtelomeric region has previously been shown to share
sequence homology with other regions of chromosome 9 (Martin et al., 2002). Consistent
with that report, probes RP11-143M1 and RP11-174M15 gave three FISH signals on a
normal chromosome 9: one at the 9p subtelomere and two others in 9p12 and 9q21.2
regions (Fig. 3.2b). However, the 9p subtelomere-specific FISH signal with clone RP11174M15 was absent in CMS6482, indicating a deletion of this region in the patient (Fig 3.2b,
Table 3.2). Probe RP11-59O6 gave a signal on the normal chromosome 9 but not on the
derivative chromosome 9 (Table 3.2). Probe RP11-910H2 gave signals on the normal
chromosome 9, as well as a reduced signal on the on the derivative chromosome 9
suggesting this probe is partially deleted (Fig. 3.2b). These results determined the deletion in
patient CMS6482 to be between genomic clones RP11-143M15 (telomeric) and RP11-910H2
(centromeric) (Fig. 3.1).

Table 3.2 Chromosome 9p BAC/PAC FISH and subtelomeric results
FISH Probe

CMS6482 - 9p24 del

CMS1485 - t(X;9)

RP11-143M1

Normal

Distal

RP11-174M15

Deleted

Distal

Deleted

NC

RP11-59O6

Deleted

Distal

RP11-910H2

Partially Deleted

Distal

RP11-165F24

Normal

Proximal

RP11-130C19

NC

Proximal

RP11-125K10

NC

Proximal

#Subtelomeric

probe 305J7T7

RP11-376O21
NC
Probes from Vysis Inc.; NC, not checked

#Subtelomeric
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Proximal

RP11-910H2

a

RP11-165F24

9

9
der(9)

der(X)
der(9)

b

305J7-T7

RP11-174M15

RP11-910H2

del(9p)
9
99
del(9)
del(9)
9

del(9p)

Figure 3.2 FISH analysis of chromosome 9p aberrations. (a) Probe RP11-910H2 (green) is distal to the 9p24.3
translocation breakpoint in CMS1485. The probe is present on the normal chromosome 9, as well as the
derivative chromosome X. Probe RP11-165F24 (green) is proximal to the 9p24 translocation breakpoint. The
probe is present on both the normal and derivative chromosome 9s(red). (b) FISH analyses in CMS6482.
305J7-T7 (green) is deleted on one chromosome 9 but not the other, indicating a subtelomeric deletion in this
patient. RP11-174M15 (green) gave a signal only on the normal chromosome 9 (red) and not on the derivative
chromosome 9 (arrow) indicating deletion of this probe in CMS6482. Consistent with reports, this probe also
gave signals at 9p12 and 9q21.1. Probe RP11-910H2 (green, arrowheads) is partially deleted on the derivative
chromosome 9 and gave signals on both the normal and the derivative chromosome 9. The chromosome 9
centromeric probe is in light red color.
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Figure 3.3 Characterization and fine mapping of DOCK8. (a) RT-PCR linking putative genes LOC389701
and FLJ00026 as part of a single gene, DOCK8. Primer locations and within the putative genes are indicated
by blue arrows. (b) Schematic diagrams (not to scale) showing the genomic structure of the DOCK8 gene (top)
and 3 variants identified through EST alignments (bottom). (c) PFGE analysis with a probe located in the 3’
portion of DOCK8 reveals an abnormally migrating fragment in CMS1485 but not in the control sample. (d)
Fine mapping of the 9p critical region with Quantitative genomic PCR in CMS1485, CMS6482, and in three
controls (CMS11195, CMS5865 and CMS6265) reveals the 9p subtelomeric deletion in CMS6482 extends at
least through exon 23 of the DOCK8 gene. CMS1485 has a deletion presumably associated with the
translocation located between exon 23 and 34 with exon 29 deleted. Standard deviation of qPCR averaged
10% and did not exceed 20%.
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Delineation of a putative critical MR region in subtelomeric 9p and identification of DOCK8
as a candidate MR gene
Sequence information corresponding to the translocation breakpoint region (Fig. 3.1)
was obtained from the NCBI database. The end sequences of BAC/PAC clones from the
critical region were analyzed further to determine the physical map of the overlapping
genomic clones. A minimal critical deletion region of approximately 230 kb in CMS6482
was determined.
In silico analysis of the gene content of the 9p24 breakpoint region and the flanking
regions showed the presence of known and putative genes (Fig. 3.1). A known gene,
FOXD4 (GenBank accession no. AY344640), is located near the telomeric end of the
deletion, and a gene CBWD1, encoding a COBW-like protein was also found in a
homologous region on human chromosome 2p13 (Martin et al., 2002). Two putative genes,
LOC389701 and FLJ00026, mapped near the proximal end of the critical 9p micro-deletion
region. EST alignments of cDNAs and rt-PCR have subsequently shown these two putative
genes to be partial sequences of a singe gene, DOCK8 (Figs. 3.3a,b). DOCK8 has
subsequently been characterized in detail (Ruusala and Aspenstrom, 2004; Takahashi et al.,
2006). The gene consists of 47 exons spanning approximately 190 kb of genomic DNA
(Fig. 3.3b).

Disruption of DOCK8 in both patients carrying 9p subtelomeric rearrangements
FISH analysis suggests that DOCK8 may be disrupted by both the translocation and
the deletion. To support these results in our translocation patient, PFGE was performed. A
DOCK8 cDNA probe detected a normal fragment of approximately 180 kb and a novel
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fragment of approximately 250 kb in patient CMS1485’s DNA digested with SalI (Fig. 3.3c).
We also performed quantitative genomic PCR and revealed a microdeletion of up to 37 kb
located between exons 23 and 34 of DOCK8 in patient CMS1485 (Fig. 3.3d).
Quantitative genomic PCR was also employed to further narrow the centromeric
boundary of the deletion in CMS6482. Five amplicons of the DOCK8 gene were analyzed
and three amplicons representing intron 13, exon 18, and exon 23 were found to be deleted
(Fig 3.3d). The deletion extends through nearly half of the 5’ end of DOCK8. The
centromeric end of the subtelomeric deletion overlaps with the microdeletion critical region
discovered in the translocation patient CMS1485 (Fig. 3.1 and 3.3d).

Characterization of DOCK8 and its expression studies
The longest DOCK8 transcript of approximate 8 kb encodes a protein of 2031aa that
contains a DOCK domain in the C-terminal region. The NCBI database analysis revealed
multiple splice variants of the DOCK8 gene. Two DOCK8 variants lacked residues 859-890
or residues 959-972 of 2031aa variant. In addition, one variant had an additional 68aa
residues at its N-terminal (NCBI, ; Takahashi et al., 2006). Analysis of the available EST
sequences further revealed two smaller variants of the gene (Fig. 3.3b). Northern analysis of
fetal and adult human tissue blots using the DOCK8 cDNA as a hybridization probe
detected a transcript of about 8.0 kb in all human tissues analyzed (data not shown). To
monitor the expression pattern in the human brain, we used Northern blots containing
RNAs from different regions of the adult human brain. A variable level of expression was
detected in all brain regions (Fig.3.4a). Furthermore, a highly expressed 1.5 kb transcript in
pancreas was identified using a 5’ cDNA probe (data not shown). Expression analysis in a
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panel of fetal cDNAs revealed the presence of DOCK8 in most tissues, including fetal brain
(Fig. 3.4b).
The tissue distribution of the splicing variants was examined through rt-PCR (Fig.
3.4c,d). All three variants of the DOCK8 were expressed at variable levels in all tissues
analyzed (Fig. 3.4d). A comparatively low level of expression or no expression was noted for
variant 2 in brain, heart and skeletal muscle (Fig. 3.4d, middle panel).
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Figure 3.4 Tissue expression profile of DOCK8. (a) Northern blot probed with a DOCK8 cDNA probe
spanning exons 22-25 shows a primary transcript at about 8kb present in most brain structures identified by the
black arrow. (b) cDNA expression panel shows DOCK8 is expressed in multiple tissues, including brain. (c)
Schematic diagram of primer locations used in variant specific RT-PCR. (d) DOCK8 Variant 1 and 3 are
expressed in all fetal tissues tested. Variant 2 expression could only be detected in fetal lung, liver, kidney,
spleen and thymus.
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DOCK8 Mutation screening
Primers were designed flanking all DOCK8 exons (Table 3.1). Using IPS and
dHPLC, we detected alterations in patients with mental retardation (data not shown).
Subsequent sequencing of the corresponding PCR products identified six single nucleotide
changes (Table 3.3). Most of the variations were too frequent in the MR cohort and were
considered likely to be polymorphisms rather than MR causing mutations. One missense
alteration, p.L1262, which appeared to be unique, was subsequently found in 2 of 145
controls tested (Table 3.3).

Table 3.3

Sequence variants detected in the DOCK8 gene

Nucleotide
change

Location

Amino acid change

IVS4+14A>G

Intron 4

None

IVS4+65G>A

Intron 4

None

c.391C>T

Exon 4

p.S97L

c.3885C>G

Exon 30

p.L1262V

c.5129G>A

Exon 44

p.P1876P

c.5805G>C

Exon 44

p.A1902P

* New single nucleotide variation
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Allele frequency
10/145 MR
patients
44/145 MR
patients
Observed in
control
1/145 MR patients
2/160 controls
26/145 MR
patients
18/145 MR
patients

SNP ID
*
*
*
*
rs10491684
*

Discussion
An important cause of MR has been shown to be chromosomal abnormalities that
may result in segmental aneuploidy and alter the dosage of developmental genes. MR/DDassociated subtelomeric deletions in patients provide critical genomic intervals for the
identification of the causative genes that yield the various associated clinical features. This
study has defined the 9p subtelomeric region associated with MR/DD in two unrelated
patients. The MR-associated critical region defined here mapped further telomeric to the
previously defined 9p24.3 deletions associated with 46, XY gonadal dysgenesis and the
ANKRD15 MR locus (Ottolenghi et al., 2000; Shan et al., 2000; Lerer et al., 2005) and also
appears to be unrelated to the more common 9p minus syndrome (OMIM).
There is some evidence that suggests some 9p subtelomeric deletions may be normal
variants. Techakittiroj and coworkers reported a case of a patient with multiple congenital
anomalies and a 9p deletion (2004). Three asymptomatic individuals in this family also were
found to have a 9p subtelomeric deletion. It is unknown if the 9p deletion in this family
extends into DOCK8 gene region, or if the symptomatic individual’s deletion has expanded
as compared to the non-symptomatic family members. The finding of a genomic interval
common to two patients with MR/DD in our study would suggest a likely role of a gene
from the critical region that may influence cognitive function.
Several putative genes are located within the MR critical region. ESTs representing
CBWD1 have been found in various tissues including fetal brain, especially in the
hippocampus. One candidate is FOXD4, a member of the forkhead family of transcription
factors (Pierrou et al., 1994; Larsson et al., 1995). Many members of the forkhead family are
known to be key regulators of embryogenesis (Kaufmann and Knochel, 1996). FOXD4 is
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widely expressed, most prominently in heart and skeletal muscle (Pierrou et al., 1994).
Mutations in FOX genes have been implicated in several human disorders (OMIM),
including the involvement of the FOXP2 gene at 7q31 in a severe speech and language
disorder (Lai et al., 2001). C9orf66 was considered to be a less likely candidate, showed no
similarity to known proteins, and ESTs representing this putative gene were isolated only
from kidney, testis and prostate cDNA libraries (UniGene Hs.190877).
DOCK8 was found to be physically disrupted both by the 9p24 translocation
breakpoint the 9p subtelomeric deletion, which suggests this to be a likely candidate for the
MR, a common clinical feature observed in both patients. DOCK8 is expressed in both fetal
and adult brain. DOCK8 belongs to the dedicator of cytokinesis (DOCK) family of proteins.
These are potential guanine nucleotide exchange factors, which activate some GTPases.
Ruusala and Aspenström have shown through yeast two-hybrid experiments that DOCK8
interacts with CDC42, a small GTPase of the Rho-subfamily (2004). Additionally, they have
shown through immunofluorescence staining has shown that DOCK8 is present at the cell
edges in areas undergoing lamellipodia formation. This data suggests a potential role of
DOCK8 in the organization of filamentous actin.
In an attempt to examine a likely involvement of DOCK8 in organization of
filamentous actin, fluorescence microscopy was performed with the actin stain phalloidin on
the X;9 translocation cell line (CMS1485) and a control fibroblast cell line. No measurable
difference in actin organization or cell size was observed between the control and patient
cells (Fig. 3.5). A scratch wound heal assay was also performed in an attempt to assay cell
motility. Again, no appreciable difference was observed between the control and patient cell
lines (data not shown). The lack of any measurable differences could be explained by the
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low level of expression of DOCK8 in the fibroblast cell lines. It is also likely that the
haploinsufficiency of DOCK8 may not cause phenotypic changes visible at the microscopic
level.

CMS11195

CMS1485

Figure 3.5 Actin structure of fibroblast cell lines CMS11195 (control) and CMS1485
(Patient). Filamentous actin was detected by Alexa Fluor® 488 phalloidin green and the cells
were examined by immunofluorescence microscopy. The nucleus is visualized using
SYTOX® orange.

The physiological and biological significance of the DOCK8 variants remain
unknown. Recently, a homozygous deletion, including the DOCK8 locus at chromosome
9p24, has been found in a human lung cancer cell line (Takahashi et al., 2006). Furthermore,
localization of DOCK8 protein in lamellipodia suggests that it might have a role in cell
migration, morphology, adhesion and growth. Further functional analysis of the DOCK8
isoforms are needed to elucidate the biological and any pathogenic consequences of DOCK8
mutations.
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Other members of the DOCK family of proteins play roles in neuronal development
and function. A defect of the DOCK3 gene has been shown in a patient with an attention
deficit hyperactivity disorder-like phenotype (de Silva et al., 2003). Furthermore, a Rac
GTPase activator protein, DOCK7, has been shown to have a role in axon formation and
neuronal polarity (Watabe-Uchida et al., 2006). Several genes involved in Rho GTPase
regulation and signaling have been linked to mental retardation (Govek et al., 2005). The
interaction of DOCK8 with a CDC42 suggests a possible mechanism whereby the disruption
of DOCK8 in our patients may results in their impaired cognitive ability. Further analysis of
the DOCK8 gene mutations in patients with MR, as well as functional analysis in animal
models, should clarify the possible involvement of DOCK8 in brain development and
function.
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CONCLUSIONS

The study of ectodermal dysplasia and its associated clinical features is an active area
of research that has helped further the understanding of how ectodermal appendages change
from undifferentiated ectodermal tissue into highly specialized and diverse structures. The
work presented herein helps add to the functional understanding of EDA, has presented
novel candidate genes involved in the pathway, and has identified novel candidate genes
involved in neural development and or function.
The first chapter presented describes the functional analysis of the N-terminal
portion of the EDA protein. Yeast two-hybrid screens with N-EDA have identified RBM39
as a possible protein interacting partner. Through co-localization experiments aimed at
supporting this interaction, the N-terminal portion of EDA was found to localize specifically
to the nucleus in COS-7 cells. This, combined with the identification of RBM39 as a
candidate protein interactor, has opened new areas of research into the function of EDA
and has suggested a link between N-EDA and estrogen receptors through RBM39.
The second chapter describes the identification of translocation critical regions
located on chromosomes 1p21 and 6p22. The patient affected with this translocation
presented with HED and mild developmental delay. Translocation breakpoints were
narrowed to 52.7 kb on chromosome 1 and 150 kb on chromosome 6. Initial analysis of the
candidate genes has revealed no changes in expression. Several candidate genes are not
expressed in the tissue available for analysis. Future studies of the candidate genes identified
here should help reveal if either translocation critical region is the cause of the HED or
developmental delay seen in the patient.
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The third chapter presents evidence that DOCK8 is physically disrupted in two
patients with 9p subtelomeric aberrations. DOCK8 is characterized at the genomic level and
three splice variants have been identified through EST database analysis and RT-PCR. The
primary isoform is disrupted in both patients with MR. Expression of the primary isoform
in the brain is also demonstrated. Since DOCK8 has been suggested to have a role in actin
structure and function by regulated CDC42, actin function and gross organization was tested
in a fibroblast cell line of one patient. No differences could be identified between fibroblast
from the patient with the X;9 translocation disrupting DOCK8 and controls. In conclusion,
the findings of this study indicate that haploinsufficiency of DOCK8 is likely responsible for
the MR in these two patients and suggest a putative role for DOCK8 in brain development
and function.
The studies presented herein have helped to further the understanding of ectodermal
appendage differentiation through the discovery of previously unknown functions of NEDA and through the identification of new candidate genes involved in EDs. Finally, these
studies have provided a possible explanation for the additional clinical feature of MR seen in
two ED patients, and in doing so, have identified new genes associated with autosomal MR.

84

APPENDICES

85

86

Appendix A
Investigation into the interaction between the EGF and EDA

Introduction
The ectodermal dysplasia (ED) signaling pathway has been elucidated from the
proteolytic release of the soluble TNF-like ligand through receptor binding and ultimate NFkB activation resulting in changes to transcriptional levels of target genes (Fig. P.2) (Cui and
Schlessinger, 2006). Several lines of evidence also suggests a possible link between the EDA
signaling and epidermal growth factor (EGF), specifically the epidermal growth factor
receptor (EGFR).
The tabby (ta) mouse, a model for X-linked ED, has loss of functional eccrine sweat
glands and delayed eyelid opening as two of the features of its ED phenotype. Treatment
with high doses of exogenous EGF can restore functional eccrine sweat glands in tabby mice
(Blecher et al., 1990). Ta Mice treated with exogenous EGF show accelerated eyelid opening
as compared to their untreated littermates effectively ameliorating the tabby phenotype
(Kapalanga and Blecher, 1991). Fibroblasts from tabby mice and HED patients, including
AnLy, have been shown to express EGFR at significantly lower levels than controls at both
the mRNA and protein levels (Vargas et al., 1996; Cui et al., 2002). Furthermore, exogenous
EGF can block the formation of hair follicles, sweat glands, sebaceous glands, and dermal
papillae, all structures under EDA control (Adelson et al., 1997). Restoration of EDA-A1
through a transgene has also been found to restore EGFR expression to wildtype levels (Cui
et al., 2002).
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However, others have reported that there is, in fact, no apparent link between EDA
and EGFR. A431 cells transiently transfected with Ta-A1 show no difference in EGFR
receptor expression levels (Mikkola et al., 1999). Additionally, the authors showed that TaA1 was not present in EGFR endocytosed vacuoles providing no support for a physical
interaction between EDA and EGFR. Unfortunately, the authors used a cell line that
already had high levels of EGFR expression for these experiments. As a result, any effect
caused by the introduction of EDA into the cell could have been muted. The absence of
EDA from EGFR endocytosed vacuoles would be expected if EGFR was a target of EDA
through the signaling pathway as opposed to a direct interaction.
This study attempts to clarify the potential link between EDA and EGFR,
specifically in human. An EDA-A1 expression construct was created and transiently
transfected into the AnLy cell line in which EDA has been shown to be disrupted.
However, RT-PCR and western analysis of EGFR in the transiently transfected cells
revealed no differences in expression.

Methods
Expression Constructs
EDA-A1 was amplified out of a fetal kidney cDNA library (Clontech) using the
primers listed in Table A.1. The amplicon was cloned into the pcDNA3.1D/V5-HisTOPO® vector as previously described. The sequence and reading frame were verified by
sequencing. A plasmid preparation of the construct was prepared using the PureYield™
plasmid midiprep system (Promega).
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Primary Human Fibroblast Cell Culture
Fibroblast cell lines corresponding to patient the CMS1485 (GM00705A) and a
control sample CMS11195 (GM03652F) were obtained from NIGMS human genetic mutant
cell repository, Coriell Institute for Medical Research (Camden, NJ). The cells were cultured
in Eagle's Minimum Essential Medium with Earle’s BSS 2X concentration of essential and
non-essential amino acids and vitamins (Sigma). The media was supplemented with 15%
FBS and 2 mM L-glutamine. Standard protocols already discussed were used in cell culture,
as well as DNA, RNA, and protein isolations.

Table A.1 Primer List
Primer Name
EDA-A1
ORF+Kozak F/R
RPII F/R
EGFR cDNA
3F/R

Sequence (5’-3’)

Used For

caccatgggctacccggaggtggag
gctgttcccttcgcccgcccgggc
gcaccacgtccaatgacat
gtgcggctgcttccataa
ccaagggagtttgtggagaa
cttccagaccagggtgttgt

EDA-A1 transfection
construct
RT-PCR control
primers
EGFR RT-PCR
primers

Annealing
Temperature
(°C)

Amplicon
Size (bp)

55

1175

60

267

56

192

Primary Human Fibroblast Transfections
Patient fibroblasts (CMS1485; GM00705A) were seeded at a density of 250,000 cells
in plating media (DMEM with 1% FBS) onto 60 mm cell culture dishes (Falcon). Cells were
transfected with 4 Rg of the appropriate vector using the Effectine (Qiagen) transfection kit
with a ration of 1:10 (DNA:Effectine). The transfection mix was applied to the cells for 5

89

hours after which the cells were washed in PBS and grown for 48 hours in complete EMEM
media.

Fluorescence Microscopy
The fibroblast cell line CMS1485 was seeded onto Nunc Lab-Tek II CC2 chambered
slides (Nalge Nunc International) at a density of 15,000 cells per well. Anti-V5 mouse
monoclonal antibody was visualized though conjugation with Alexa Flour® 594 goat antimouse (Invitrogen). Actin was visualized through staining with Alexa Fluor® 488 phalloidin
green (N-EDA). Briefly, cells were washed two times with PBS and fixed with 4% paraformaldehyde for 5 minutes. The cells were then permeabilized with 0.1% Triton X-100 in
PBS for 5 minutes followed by washing twice with PBS. Next, the cells were incubated with
a quenching solution (1.02 g sodium acetate in 50 ml PBS) twice for 8 minutes each. Cells
were then incubated for 30 minutes in a blocking solution (2% horse serum, 0.4% BSA in
PBS) with 200 Rg/ml RNaseA. Primary antibodies were diluted 1:400 in the blocking
solution and applied to the cells for 1 hour at room temperature. Cells were rinsed 3 times 5
minutes each with blocking solution followed by a final rinse in TS (10mM Tris-HCl pH 7.5,
15 mM NaCl). Secondary antibodies diluted 1:2000 in blocking solution were then added to
the cells. The cells were then rinsed four times with PBS. Imaging was performed on an
Axiovert 200 Laser Scanning Microscope (Zeiss, Oberkochen, Germany).
EDA staining in non-permeabilized cells was performed as above, with the
exception that, after fixation, the V5 antibody staining was performed. The cells were
subsequently washed 3 times with PBS and treated with TX-100 as above.
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Real-Time RT-PCR
Real-time RT-PCR was performed using the iScript™ One-Step RT-PCR Kit with
SYBR® Green (BioRad, Hercules, CA) on an iCycler iQ™ Real-Time PCR detection System
(BioRad). Primer pair information for both the EGFR and RPII, the reference genes, are
listed in Table A.1. The cycling conditions used an initial 10 minute first strand synthesis
step at 50°C followed by a 5 minute denaturation step at 95°C. Two-step amplification was
performed by cycling between 95°C for 10 seconds and 58°C for 30 seconds 45 times. Data
was analyzed using the iCycler iQ™ software to generate a standard curve for each gene and
calculate the fluorescence generated from the experimental primer pairs relative to RPII
using the comparative Ct method.

Western Analysis of EGFR
Protein was isolated from COS-7 cells using NP-40 lysis buffer (0.1% NP-40 (Sigma)
in PBS). The protein lysate was quantified through a Bradford Protein assay (Peirce,
Rockford, IL). The protein was loaded on an 8% SDS-PAGE gel at a concentration of 10
Rg per well. The gel was run at 120 volts for 1 hour. The protein was transferred to a
nitrocellulose filter using a BioRad semidry transfer apparatus. The resulting filter was
blocked in Tris-buffered saline, 0.2% Tween-20, and 5% powdered milk overnight at 4°C.
EGFR polyclonal antibody was added epitope at a dilution of 1:400 for 1 hour at room
temperature. Secondary antibody was added for 1 hour at room temperature.
SuperSignal®West Dura Extended Duration Substrate (Pierce) was used for
chemiluminescent detection. Western blots were stripped with Restore™ Western Blot
Stripping Buffer (Pierce) and re-probed with anti N-actin antibodies as a control.
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Results
Expression of EDA-A1 in CMS1485
The CMS1485 cell line has been previously shown to have ectodermal dysplasia as a
result of a translocation disrupting EDA within intron 1 (MacDermot and Hulten, 1990;
Thomas et al., 1993; Kere et al., 1996; Srivastava et al., 1996). This cell line has also been
shown to have reduced EGFR expression as compared to normal cell lines (Vargas et al.,
1996; Cui et al., 2002). In order to determine if restoration of EDA-A1 signaling in the
CMS1485 cell line would restore EGFR expression to wild-type levels, we inserted a
functional copy of EDA-A1 into this cell line. Transfection conditions were initially
optimized using a LacZ gene inserted into the pcDNA3.1D/V5-His-TOPO® vector.
Transfection efficiency as measured through beta galactosidase activity was determined to be
approximately 60%. However, transfection efficiency with the pcDNA3.1D/V5-HisTOPO® + EDA-A1 construct was found to be lower. Approximately 10% of the
transfected cells showed robust expression of EDA-A1. Another 30-40% of the cells
showed expression at levels closer to background.

Expression of EGFR in Presence of Transgenic EDA-A1in CMS1485
Expression of EGFR in cells transfected with the EDA-A1 construct, the empty
pcDNA3.1D/V5-His-TOPO® vector, or the LacZ constructed was measured through both
real-time RT-PCR and Western analysis. Cells transfected with EDA –A1 were not found to
have EGFR expression profiles significantly different from those cells transfected with
empty vector (Fig. A1). RT-PCR with an EGFR primer pair normalized to RPII found
EGFR expression in EDA-A1 transfected cells to be not significantly different from that
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seen in controls (Fig. A.1a). Real-time RT-PCR also revealed EGFR expression in CMS1485
was comparable to that of normal fibroblast (Fig. A.1a). Western analysis showed similar
results with protein expression (Fig. A.1b).
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Figure A.1 Expression analysis of EGFR in transfected cells. (a) Real-time RT-PCR of EGFR in a normal
fibroblast cell line (CMS11195), EDA deficient cell line (CMS1485), and an EDA deficient cell line transfected
with either EDA-A1, empty vector, or a lacZ control. No difference in expression of EGFR was seen between
any of the samples. A coding portion of RPII was used to normalize samples. (b) Western blot of transfected
cells. No difference in EGFR concentration was detected between cells transfected with EDA-A1 and those
transfected with controls.
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Figure A.2 Cellular localization of EDA-A1. (A) Cell outlines visualized by staining with phalloidin green
(green). EDA-A1intracellular location visualized through V5 epitope (red) and is present in a lattice like
appearance throughout the cell as previously reported (Ezer et al., 1997). (C) EDA-A1 localized in nonpermeabilized cells. Cell outlines visualized with phalloidin green. EDA-A1 localized through V5 epitope (red)
and is present only on the cell membrane.

Cellular Localization of EDA-A1
Fluorescence microscopy of EDA-A1 transfected into COS-7 cells was performed to
determine if EDA-A1 was displaying cellular localization consistent with what has been
previously reported. The results show that EDA is found in the cytoplasm in a “lace-like”
pattern suggestive of ER-Golgi trafficking (Fig. A.2a,b). These micrographs were nearly
identical to those previously published (Ezer et al., 1997; Bayes et al., 1998; Mikkola et al.,
1999). EDA-A1 was found to be expressed on the cell membrane in a Type II orientation
(Fig A.2c,d). This is also consistent with previous reports (Ezer et al. 1997). These data
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suggest that the EDA-A1construct is being transcribed and translated and is localizing to the
cell membrane, a point that would be required for proper signaling.

Discussion
This study investigated the connection between EDA-1 and EGFR that has been
previously reported in ta mice. No increase in EGFR expression was detected in a primary
human fibroblast cell line naturally deficient in EDA function but transiently transfected
with EDA-A1
The lack of change in EGFR expression when CMS1485 was transfected with EDAA1 could be accounted for by several explanations. The most probable reason is the low
transfection efficiency. Because of the sensitive nature of this cell line to cell concentrations,
stable cell lines could not be established. High transfection efficiencies could not be
obtained again because of the sensitive nature of this cell line. As a result, only about 40%
of the cells were transfected. Of those, only about 10% expressed the EDA-A1 transgene at
high levels. Any change in EGFR expression that may have occurred as a result of the
EDA–A1 transgene was, therefore, muted out by the large number of cells either with no
EDA-A1 gene construct or expressing EDA-A1 at low levels.
Previous reports have shown EGFR expression at both the protein and mRNA level
is significantly reduced in CMS1485 as compared to other HED patients, as well as control
fibroblasts (Vargas et al., 1996). This study did not show a significant difference between
EGFR expression in the CMS1485 cell line and controls. This may be the result of one of
three possibilities. First, our control cell line obtained from the Coriell cell repository may
itself have some other mutation affecting EGFR expression that has not been previously
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identified. Second, our construct may not have produced a biologically active form of EDAA1. Receptor binding and NF-kB signaling pathway activation was not tested; however,
EDA-A1 production was examined through fluorescence microscopy. EDA-A1 was found
to be present in a type II orientation as a membrane protein. Intracellular distribution was
similar to published results with a lattice like appearance due to the protein overloading the
ER and Golgi transport mechanisms as seen previously (Ezer et al., 1997; Mikkola et al.,
1999). Most likely, the reason lies with the CMS1485 cell line. This primary cell line has
been maintained since the 1970s. As it is not an immortalized cell line, each passage brings
the cells closer to a senescent state. Passage numbers in the low twenties were used to
transfect, as well as isolate RNA and protein. It is likely that these high passage numbers
have resulted in changes in gene expression as well as the difficulty in transfecting this cell
line.
In conclusion, a direct link between EDA signaling and EGFR in human cultured
cells could not be established through this study. This finding does not exclude the
possibility that EDA-EGF/EGFR may affect the same signaling pathways through other
convergent pathways.
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